CA3099614A1 - The use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases - Google Patents
The use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases Download PDFInfo
- Publication number
- CA3099614A1 CA3099614A1 CA3099614A CA3099614A CA3099614A1 CA 3099614 A1 CA3099614 A1 CA 3099614A1 CA 3099614 A CA3099614 A CA 3099614A CA 3099614 A CA3099614 A CA 3099614A CA 3099614 A1 CA3099614 A1 CA 3099614A1
- Authority
- CA
- Canada
- Prior art keywords
- steroidal
- muscular
- treatment
- acceptable salt
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003637 steroidlike Effects 0.000 title claims abstract description 76
- 238000011282 treatment Methods 0.000 title claims abstract description 63
- 230000003387 muscular Effects 0.000 title claims abstract description 48
- 208000018360 neuromuscular disease Diseases 0.000 title claims abstract description 45
- 208000021642 Muscular disease Diseases 0.000 title claims abstract description 43
- 229940083712 aldosterone antagonist Drugs 0.000 title abstract description 18
- 239000002394 mineralocorticoid antagonist Substances 0.000 title abstract description 14
- 229940127296 soluble guanylate cyclase stimulator Drugs 0.000 claims abstract description 44
- 239000005557 antagonist Substances 0.000 claims abstract description 42
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims abstract description 36
- 230000002265 prevention Effects 0.000 claims abstract description 34
- 150000003839 salts Chemical class 0.000 claims description 45
- 150000001875 compounds Chemical class 0.000 claims description 33
- 239000003814 drug Substances 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- BTBHLEZXCOBLCY-QGZVFWFLSA-N (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide Chemical group C1([C@@H]2C(=C(C)NC=3C(C)=CN=C(C2=3)OCC)C(N)=O)=CC=C(C#N)C=C1OC BTBHLEZXCOBLCY-QGZVFWFLSA-N 0.000 claims description 15
- 229950004408 finerenone Drugs 0.000 claims description 15
- 201000006938 muscular dystrophy Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 229940127280 BAY 41-2272 Drugs 0.000 claims description 11
- ATOAHNRJAXSBOR-UHFFFAOYSA-N BAY 41-2272 Chemical compound NC1=NC(C=2C3=CC=CN=C3N(CC=3C(=CC=CC=3)F)N=2)=NC=C1C1CC1 ATOAHNRJAXSBOR-UHFFFAOYSA-N 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- QZFHIXARHDBPBY-UHFFFAOYSA-N vericiguat Chemical compound N1=C(N)C(NC(=O)OC)=C(N)N=C1C(C1=CC(F)=CN=C11)=NN1CC1=CC=CC=C1F QZFHIXARHDBPBY-UHFFFAOYSA-N 0.000 claims description 9
- 229950005018 vericiguat Drugs 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- 231100000252 nontoxic Toxicity 0.000 claims description 8
- 230000003000 nontoxic effect Effects 0.000 claims description 8
- CYSJNTQNMDWAJV-UHFFFAOYSA-N praliciguat Chemical compound C1=C(F)C(NCC(O)(C(F)(F)F)C(F)(F)F)=NC(C2=NN(CC=3C(=CC=CC=3)F)C(C3=NOC=C3)=C2)=N1 CYSJNTQNMDWAJV-UHFFFAOYSA-N 0.000 claims description 8
- 229940070116 praliciguat Drugs 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 4
- WXXSNCNJFUAIDG-UHFFFAOYSA-N riociguat Chemical compound N1=C(N)C(N(C)C(=O)OC)=C(N)N=C1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F WXXSNCNJFUAIDG-UHFFFAOYSA-N 0.000 claims description 4
- 229960000529 riociguat Drugs 0.000 claims description 3
- 101150030891 MRAS gene Proteins 0.000 abstract description 17
- 239000012190 activator Substances 0.000 abstract description 13
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 description 37
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 description 37
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 22
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 22
- 210000003205 muscle Anatomy 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 20
- 230000000694 effects Effects 0.000 description 14
- 230000037396 body weight Effects 0.000 description 13
- 229940125526 sGC activator Drugs 0.000 description 13
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 12
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 10
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 10
- 229960002478 aldosterone Drugs 0.000 description 10
- -1 2,3,6-trifluorobenzyl Chemical group 0.000 description 9
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 150000003278 haem Chemical class 0.000 description 9
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 8
- 230000008602 contraction Effects 0.000 description 8
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 description 8
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 201000006935 Becker muscular dystrophy Diseases 0.000 description 6
- 108010069091 Dystrophin Proteins 0.000 description 6
- 206010019280 Heart failures Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 244000309466 calf Species 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000004217 heart function Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000011835 investigation Methods 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 6
- 208000002815 pulmonary hypertension Diseases 0.000 description 6
- 238000009097 single-agent therapy Methods 0.000 description 6
- 229960002256 spironolactone Drugs 0.000 description 6
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 239000005541 ACE inhibitor Substances 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 5
- 229940125364 angiotensin receptor blocker Drugs 0.000 description 5
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000003752 polymerase chain reaction Methods 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 208000031229 Cardiomyopathies Diseases 0.000 description 4
- 102000001039 Dystrophin Human genes 0.000 description 4
- 208000029549 Muscle injury Diseases 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000009084 cardiovascular function Effects 0.000 description 4
- 229950002128 cinaciguat Drugs 0.000 description 4
- WPYWMXNXEZFMAK-UHFFFAOYSA-N cinaciguat Chemical compound C=1C=C(C(O)=O)C=CC=1CN(CCCCC(=O)O)CCC1=CC=CC=C1OCC(C=C1)=CC=C1CCC1=CC=CC=C1 WPYWMXNXEZFMAK-UHFFFAOYSA-N 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 229960001208 eplerenone Drugs 0.000 description 4
- JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 230000004220 muscle function Effects 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000008327 renal blood flow Effects 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
- 125000006508 2,6-difluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C(F)=C1[H])C([H])([H])* 0.000 description 3
- MBKYLPOPYYLTNW-ZDUSSCGKSA-N 2-[(3S)-7-fluoro-4-(3-oxo-4H-1,4-benzoxazine-6-carbonyl)-2,3-dihydro-1,4-benzoxazin-3-yl]-N-methylacetamide Chemical compound FC1=CC2=C(N([C@H](CO2)CC(=O)NC)C(=O)C=2C=CC3=C(NC(CO3)=O)C=2)C=C1 MBKYLPOPYYLTNW-ZDUSSCGKSA-N 0.000 description 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 3
- UXHQLGLGLZKHTC-CUNXSJBXSA-N 4-[(3s,3ar)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3,3a,4,5-tetrahydropyrazolo[3,4-f]quinolin-2-yl]-2-chlorobenzonitrile Chemical compound C1CC(O)CCN1C(=O)C1=CC=C(C=2[C@@H]([C@H](C3CCCC3)N(N=2)C=2C=C(Cl)C(C#N)=CC=2)CC2)C2=N1 UXHQLGLGLZKHTC-CUNXSJBXSA-N 0.000 description 3
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
- 229940126320 balcinrenone Drugs 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003176 fibrotic effect Effects 0.000 description 3
- ZMBYQTGAXZOMOO-UHFFFAOYSA-N imidazo[1,2-a]pyridine-3-carboxamide Chemical compound C1=CC=CN2C(C(=O)N)=CN=C21 ZMBYQTGAXZOMOO-UHFFFAOYSA-N 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 201000001881 impotence Diseases 0.000 description 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- PWQSMBODNGQNOZ-UHFFFAOYSA-N 2,2,2-trifluoroethylcarbamic acid Chemical compound OC(=O)NCC(F)(F)F PWQSMBODNGQNOZ-UHFFFAOYSA-N 0.000 description 2
- WQKHERPPDYPMNX-UHFFFAOYSA-N 6-chloro-3,4-dihydro-2h-naphthalen-1-one Chemical compound O=C1CCCC2=CC(Cl)=CC=C21 WQKHERPPDYPMNX-UHFFFAOYSA-N 0.000 description 2
- 102000005862 Angiotensin II Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 description 2
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 description 2
- 108010007859 Lisinopril Proteins 0.000 description 2
- 201000001087 Miyoshi muscular dystrophy Diseases 0.000 description 2
- 208000009376 Miyoshi myopathy Diseases 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 206010028424 Myasthenic syndrome Diseases 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 206010049418 Sudden Cardiac Death Diseases 0.000 description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 description 2
- 206010042953 Systemic sclerosis Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 201000006815 congenital muscular dystrophy Diseases 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 229910001651 emery Inorganic materials 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 239000007943 implant Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 2
- 229960002394 lisinopril Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000003274 myotonic effect Effects 0.000 description 2
- 210000001087 myotubule Anatomy 0.000 description 2
- 150000002823 nitrates Chemical class 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000005801 respiratory difficulty Effects 0.000 description 2
- 206010039722 scoliosis Diseases 0.000 description 2
- 208000007056 sickle cell anemia Diseases 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003270 steroid hormone Substances 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- YFJKHTZXXMBJEW-UHFFFAOYSA-N 2-[(4-chlorophenyl)sulfonylamino]-4,5-dimethoxy-n-(4-thiomorpholin-4-ylsulfonylphenyl)benzamide Chemical compound C=1C=C(S(=O)(=O)N2CCSCC2)C=CC=1NC(=O)C=1C=C(OC)C(OC)=CC=1NS(=O)(=O)C1=CC=C(Cl)C=C1 YFJKHTZXXMBJEW-UHFFFAOYSA-N 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 description 1
- LIVYVCAUBHXIMI-UHFFFAOYSA-N 5-fluoro-2-[1-[(2-fluorophenyl)methyl]-5-(1,2-oxazol-3-yl)pyrazol-3-yl]-1h-pyrimidin-6-one Chemical compound C1=C(F)C(O)=NC(C2=NN(CC=3C(=CC=CC=3)F)C(C3=NOC=C3)=C2)=N1 LIVYVCAUBHXIMI-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 229940127260 BI-703704 Drugs 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010017577 Gait disturbance Diseases 0.000 description 1
- 206010020571 Hyperaldosteronism Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023201 Joint contracture Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 description 1
- 208000007623 Lordosis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000097724 Mesua ferrea Species 0.000 description 1
- 235000010931 Mesua ferrea Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010062575 Muscle contracture Diseases 0.000 description 1
- 208000021908 Myocardial disease Diseases 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000005704 Olneya tesota Nutrition 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 235000008198 Prosopis juliflora Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101100372319 Rattus norvegicus Utrn gene Proteins 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 206010041277 Sodium retention Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 206010068872 Toe walking Diseases 0.000 description 1
- 102000013394 Troponin I Human genes 0.000 description 1
- 108010065729 Troponin I Proteins 0.000 description 1
- 102000011856 Utrophin Human genes 0.000 description 1
- 108010075653 Utrophin Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 210000001361 achilles tendon Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000002517 constrictor effect Effects 0.000 description 1
- 230000009091 contractile dysfunction Effects 0.000 description 1
- 208000006111 contracture Diseases 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000002592 echocardiography Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 125000004175 fluorobenzyl group Chemical group 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 201000000079 gynecomastia Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000001023 inorganic pigment Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000019948 ion homeostasis Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 235000013980 iron oxide Nutrition 0.000 description 1
- VBMVTYDPPZVILR-UHFFFAOYSA-N iron(2+);oxygen(2-) Chemical class [O-2].[Fe+2] VBMVTYDPPZVILR-UHFFFAOYSA-N 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000007425 progressive decline Effects 0.000 description 1
- 208000026526 progressive weakness Diseases 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 201000003004 ptosis Diseases 0.000 description 1
- 125000004353 pyrazol-1-yl group Chemical group [H]C1=NN(*)C([H])=C1[H] 0.000 description 1
- 125000004941 pyridazin-5-yl group Chemical group N1=NC=CC(=C1)* 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000033904 relaxation of vascular smooth muscle Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical group 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000007497 verbal memory Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The present invention relates to non-steroidal mineralocorticoid receptor antagonists (MR Antagonists, MRAs) alone or preferably in combination with sGC stimulators and/or sGC activators, for use in the prevention and/or treatment of muscular or neuromuscular diseases, especially for use in the treatment of Duchenne Muscular Dystrophy (DMD).
Description
The use of non-steroidal Mineralocorticoid Receptor Antagonists alone or in combination for the treatment of muscular or neuromuscular diseases The present invention relates to non-steroidal mineralocorticoid receptor (MR) and the pharmacology of mineralocorticoid receptor antagonists (MR Antagonists, MRAs). In particular, the invention relates to the use of MRAs alone and in combination preferably in combination with sGC
stimulators and/or sGC
activators for preparation of medicaments for the prevention and/or treatment of muscular or neuromuscular diseases, especially for the treatment of Duchenne Muscular Dystrophy (DMD).
Background of the invention Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder that affects approximately 1 in 5000 newborn human males in whom absence of the sarcolemmal protein dystrophin causes degeneration of skeletal and cardiac muscle. Males with DMD develop cardiomyopathy and typically die in the third or fourth decade of life. Importantly, myocardial disease is developing in DMD
patients long before left ventricular (LV) function becomes abnormal. Therefore, current guidelines recommend that well established heart failure drugs such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) should be given once there is evident left ventricular systolic dysfunction. However, despite these treatments, the ability to walk may be already lost as teenager, requiring a wheelchair. Breathing difficulties and heart disease usually start by age 20 and the current life expectancy is around 30 years. There is no cure and a substantial unmet medical need to improve and prolong life in muscular dystrophies and DMD
patients.
The cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), were discovered decades ago and represent one of the most important second messenger pathway within cells. It is well established that the regulation of intra-cellular cGMP pools have substantial impact on physiology, and pathophysiology and is one basic principle of pharmacological intervention [Evgenov et al.
Nat Rev Drug Discov. 2006 Sep;5(9):755-68; Schmidt HH et al. Handbook of Experimental Pharmacology 2009 (191)].
Nitrates and PDE5 inhibitors (PDE5i) which could increase intra-cellular cGMP
levels are therefore already approved therapies for Angina Pectoris, and Pulmonary Hypertension (PAH) or Erectile Dysfunction (ED), respectively. More recently discovered sGC stimulators can overcome significant limitations of Nitrates and PDE5i by direct stimulation of the soluble guanylate cyclase (sGC). The sGC
stimulators like Riociguat are approved for the treatment of Pulmonary Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) or are in late stage Phase III clinical development for the treatment of Heart Failure
stimulators and/or sGC
activators for preparation of medicaments for the prevention and/or treatment of muscular or neuromuscular diseases, especially for the treatment of Duchenne Muscular Dystrophy (DMD).
Background of the invention Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder that affects approximately 1 in 5000 newborn human males in whom absence of the sarcolemmal protein dystrophin causes degeneration of skeletal and cardiac muscle. Males with DMD develop cardiomyopathy and typically die in the third or fourth decade of life. Importantly, myocardial disease is developing in DMD
patients long before left ventricular (LV) function becomes abnormal. Therefore, current guidelines recommend that well established heart failure drugs such as angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) should be given once there is evident left ventricular systolic dysfunction. However, despite these treatments, the ability to walk may be already lost as teenager, requiring a wheelchair. Breathing difficulties and heart disease usually start by age 20 and the current life expectancy is around 30 years. There is no cure and a substantial unmet medical need to improve and prolong life in muscular dystrophies and DMD
patients.
The cyclic nucleotides, cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), were discovered decades ago and represent one of the most important second messenger pathway within cells. It is well established that the regulation of intra-cellular cGMP pools have substantial impact on physiology, and pathophysiology and is one basic principle of pharmacological intervention [Evgenov et al.
Nat Rev Drug Discov. 2006 Sep;5(9):755-68; Schmidt HH et al. Handbook of Experimental Pharmacology 2009 (191)].
Nitrates and PDE5 inhibitors (PDE5i) which could increase intra-cellular cGMP
levels are therefore already approved therapies for Angina Pectoris, and Pulmonary Hypertension (PAH) or Erectile Dysfunction (ED), respectively. More recently discovered sGC stimulators can overcome significant limitations of Nitrates and PDE5i by direct stimulation of the soluble guanylate cyclase (sGC). The sGC
stimulators like Riociguat are approved for the treatment of Pulmonary Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) or are in late stage Phase III clinical development for the treatment of Heart Failure
-2-(HFrEF). Moreover, additional sGC stimulators are in earlier stages of clinical development and preclinical investigation including e.g. Hypertension (HTN), Chronic Kidney Diseases (CKD), Systemic Sclerosis (SSc), Cystic Fibrosis (CF), Sickle Cell Disease (SCD) and others. This very broad treatment potential of sGC stimulators underpins this very effective and broad pharmacological intervention strategy for various diseases. The sGC stimulators bind to the alpha subunit of the non-oxidized and heme-containing sGC
which leads to NO-independent formation and increase of intracellular cGMP. In addition, the sGC
stimulators enhance the NO-effect on cGMP when NO is bound to the sGC [Stasch JP et al., Nature 2001, 410:212-215; ; Stasch JP and Hobbs AJ. Handb. Exp. Pharmacol. 2009, 191, 277 ¨
308]. If the heme group is removed from the soluble guanylate cyclase, the remaining catalytic basal activity of the heme-free enzyme cannot be anymore stimulated by the sGC stimulators and also not by NO
[Evgenov OV, Pacher P, Schmidt PM, Hask6 G, Schmidt HH, Stasch JP. Nat Rev Drug Discov. 2006 Sep;5(9):755-68]. This observation is important since heme-free and oxidized forms of the sGC are preferentially present at diseases which are linked to ischemic and hypoxic conditions and oxidative stress. The current understanding is that under oxidative stress conditions, the Fe' iron atom of the heme group is oxidized to Fe 3+ which destabilizes the binding of the heme group to the beta-subunit and renders the enzyme heme-free. With the discovery of BAY 58-2667 (Cinaciguat) a new chemical matter was identified which is able to activate heme-free sGC. Therefore BAY 58-2667 is the prototype of this class of sGC activators.
Common characteristics of these substances are that the activation of the oxidized or heme-free enzyme is markedly higher than that of the heme-containing enzyme and that in combination with NO they have an additive effect on enzyme activation [Evgenov et al., ibid.; J.P. Stasch et al., Br. I Pharmacol. 136 (2002), 773; J.P. Stasch et al., J. Chn. Invest. 116 (2006), 2552]. More recently also other classes of sGC activators have been discovered, different in chemical structures, different in pharmacokinetic and pharmacodynamics profiles, but also different in organ distribution.
It is well established that cGMP increase by sGC stimulators leads to relaxation of vascular smooth muscle cells and blood pressure decrease. However, other modes of actions beyond vasodilation and targeting the vascular smooth muscle cells are only partly understood and are currently under investigation. In recent years it became obvious that cGMP increase might have impact also on cardiomyocyte and skeletal muscle cell function. Moreover, alterations in the NO/cGMP system driven by NOS (NO-Synthase) could be involved in the pathology of neuromuscular disorders and muscular dystrophies.
In line with this, it was published previously that i.e. NO donors and PDE5 inhibitors showed beneficial effects in nonclinical animal models of muscular dystrophies [Thomas GD et al., PLoS One.
2012;7(11):e49350; Ramachandran J
et al., Biochem 1 2013 Jan 1;449(1):133-42; Thomas GD et al., Front Physiol.
2013 Dec 18;4:381; Adamo CM et al. Proc Natl Acad Sci. 2010 Nov2;107(44):19079-83; Percival JM et al., J Pathol. 2012 Sep;228(1):77-87] or i.e. PDE5 inhibitor treatment was beneficial in patients with Duchenne Muscular
which leads to NO-independent formation and increase of intracellular cGMP. In addition, the sGC
stimulators enhance the NO-effect on cGMP when NO is bound to the sGC [Stasch JP et al., Nature 2001, 410:212-215; ; Stasch JP and Hobbs AJ. Handb. Exp. Pharmacol. 2009, 191, 277 ¨
308]. If the heme group is removed from the soluble guanylate cyclase, the remaining catalytic basal activity of the heme-free enzyme cannot be anymore stimulated by the sGC stimulators and also not by NO
[Evgenov OV, Pacher P, Schmidt PM, Hask6 G, Schmidt HH, Stasch JP. Nat Rev Drug Discov. 2006 Sep;5(9):755-68]. This observation is important since heme-free and oxidized forms of the sGC are preferentially present at diseases which are linked to ischemic and hypoxic conditions and oxidative stress. The current understanding is that under oxidative stress conditions, the Fe' iron atom of the heme group is oxidized to Fe 3+ which destabilizes the binding of the heme group to the beta-subunit and renders the enzyme heme-free. With the discovery of BAY 58-2667 (Cinaciguat) a new chemical matter was identified which is able to activate heme-free sGC. Therefore BAY 58-2667 is the prototype of this class of sGC activators.
Common characteristics of these substances are that the activation of the oxidized or heme-free enzyme is markedly higher than that of the heme-containing enzyme and that in combination with NO they have an additive effect on enzyme activation [Evgenov et al., ibid.; J.P. Stasch et al., Br. I Pharmacol. 136 (2002), 773; J.P. Stasch et al., J. Chn. Invest. 116 (2006), 2552]. More recently also other classes of sGC activators have been discovered, different in chemical structures, different in pharmacokinetic and pharmacodynamics profiles, but also different in organ distribution.
It is well established that cGMP increase by sGC stimulators leads to relaxation of vascular smooth muscle cells and blood pressure decrease. However, other modes of actions beyond vasodilation and targeting the vascular smooth muscle cells are only partly understood and are currently under investigation. In recent years it became obvious that cGMP increase might have impact also on cardiomyocyte and skeletal muscle cell function. Moreover, alterations in the NO/cGMP system driven by NOS (NO-Synthase) could be involved in the pathology of neuromuscular disorders and muscular dystrophies.
In line with this, it was published previously that i.e. NO donors and PDE5 inhibitors showed beneficial effects in nonclinical animal models of muscular dystrophies [Thomas GD et al., PLoS One.
2012;7(11):e49350; Ramachandran J
et al., Biochem 1 2013 Jan 1;449(1):133-42; Thomas GD et al., Front Physiol.
2013 Dec 18;4:381; Adamo CM et al. Proc Natl Acad Sci. 2010 Nov2;107(44):19079-83; Percival JM et al., J Pathol. 2012 Sep;228(1):77-87] or i.e. PDE5 inhibitor treatment was beneficial in patients with Duchenne Muscular
-3-Dystrophies (DMD) [Nelson MD et al., Neurology. 2014 Jun 10;82(23):2085-91]
and Becker Muscular Dystrophy (BMD) [Martin EA et al., Sci Transl Med. 2012 Nov 28;4(162):162ra155]. However, recent clinical trials delivered conflicting results and PDE5 inhibitor treatment failed to show a beneficial effect in patients [Leung DG et al., Ann Neurol. 2014 Oct;76(4):541-9; Victor RG et al., Neurology. 2017 Oct 24;89(17):1811-1820] despite promising preclinical results including preclinical models in which sGC
stimulators were used (WO 2015/106268 Al). This could be due to the fact that PDE5 inhibitors and sGC
stimulators might be only effective when sufficient NO/cGMP is produced (PDE5i) and when sufficient heme-containing sGC is expressed. Both sufficient endogenous cGMP production and expression of heme-containing sGC might be impaired in muscular dystrophies. In addition, dysregulation of the NO/cGMP/PDE axis might only be in part responsible for the development and progression of muscular dystrophies. Other pathways could also significantly contribute to the disease phenotype and diseases severity of muscular dystrophies. More recently, Ironwood Pharmaceuticals claimed the use of sGC
stimulators for treatment of DMD (WO 2015/106268 Al) and Johns Hopkins claimed the use of sGC
activators for the treatment of DMD (WO 2014/190250 Al).
Aldosterone plays a key part in maintaining fluid and electrolyte homeostasis by promoting, in the epithelium of the distal nephron, sodium retention and potassium secretion, thus contributing to keeping the extracellular volume constant and thus to regulating blood pressure. Besides this, aldosterone displays direct effects on the structure and function of the cardiac and vascular system, but the underlying mechanisms thereof are not yet fully explained [R.E. Booth, J.P. Johnson, J.D. Stockand, Adv. Physiol. Educ. 26 (1), 8-20 (2002)].
Aldosterone is a steroid hormone which is formed in the adrenal cortex. Its production is regulated indirectly very substantially depending on the renal blood flow. Any decrease in renal blood flow leads to release in the kidney of the enzyme renin into the circulating blood. This in turn activates the formation of angiotensin II, which on the one hand has a constricting effect on the arterial blood vessels, but on the other hand also stimulates the formation of aldosterone in the adrenal cortex. Thus, the kidney acts as blood pressure sensor, and thus indirect volume sensor in the circulating blood and counteracts via the renin-angiotensin-aldosterone system critical losses of volume by on the one hand increasing the blood pressure (angiotensin II effect), and on the other hand by rebalancing the state of filling of the vascular system by increased reabsorption of sodium and water in the kidney (aldosterone effect).
This control system may be pathologically impaired in diverse ways. Thus, a chronic reduction in renal blood flow (e.g. as a result of heart failure and the congestion of blood in the venous system caused thereby) leads to a chronically excessive release of aldosterone. In turn this is followed by an expansion of the blood volume and thereby increases the weakness of the heart through an excessive supply of volume to the heart.
and Becker Muscular Dystrophy (BMD) [Martin EA et al., Sci Transl Med. 2012 Nov 28;4(162):162ra155]. However, recent clinical trials delivered conflicting results and PDE5 inhibitor treatment failed to show a beneficial effect in patients [Leung DG et al., Ann Neurol. 2014 Oct;76(4):541-9; Victor RG et al., Neurology. 2017 Oct 24;89(17):1811-1820] despite promising preclinical results including preclinical models in which sGC
stimulators were used (WO 2015/106268 Al). This could be due to the fact that PDE5 inhibitors and sGC
stimulators might be only effective when sufficient NO/cGMP is produced (PDE5i) and when sufficient heme-containing sGC is expressed. Both sufficient endogenous cGMP production and expression of heme-containing sGC might be impaired in muscular dystrophies. In addition, dysregulation of the NO/cGMP/PDE axis might only be in part responsible for the development and progression of muscular dystrophies. Other pathways could also significantly contribute to the disease phenotype and diseases severity of muscular dystrophies. More recently, Ironwood Pharmaceuticals claimed the use of sGC
stimulators for treatment of DMD (WO 2015/106268 Al) and Johns Hopkins claimed the use of sGC
activators for the treatment of DMD (WO 2014/190250 Al).
Aldosterone plays a key part in maintaining fluid and electrolyte homeostasis by promoting, in the epithelium of the distal nephron, sodium retention and potassium secretion, thus contributing to keeping the extracellular volume constant and thus to regulating blood pressure. Besides this, aldosterone displays direct effects on the structure and function of the cardiac and vascular system, but the underlying mechanisms thereof are not yet fully explained [R.E. Booth, J.P. Johnson, J.D. Stockand, Adv. Physiol. Educ. 26 (1), 8-20 (2002)].
Aldosterone is a steroid hormone which is formed in the adrenal cortex. Its production is regulated indirectly very substantially depending on the renal blood flow. Any decrease in renal blood flow leads to release in the kidney of the enzyme renin into the circulating blood. This in turn activates the formation of angiotensin II, which on the one hand has a constricting effect on the arterial blood vessels, but on the other hand also stimulates the formation of aldosterone in the adrenal cortex. Thus, the kidney acts as blood pressure sensor, and thus indirect volume sensor in the circulating blood and counteracts via the renin-angiotensin-aldosterone system critical losses of volume by on the one hand increasing the blood pressure (angiotensin II effect), and on the other hand by rebalancing the state of filling of the vascular system by increased reabsorption of sodium and water in the kidney (aldosterone effect).
This control system may be pathologically impaired in diverse ways. Thus, a chronic reduction in renal blood flow (e.g. as a result of heart failure and the congestion of blood in the venous system caused thereby) leads to a chronically excessive release of aldosterone. In turn this is followed by an expansion of the blood volume and thereby increases the weakness of the heart through an excessive supply of volume to the heart.
-4-Congestion of blood in the lungs with shortness of breath and formation of edema in the extremities, and ascites and pleural effusions may be the result; the renal blood flow falls further. In addition, the excessive aldosterone effect leads to a reduction in the potassium concentration in the blood and in the extracellular fluid. In heart muscles which have been previously damaged otherwise, cardiac arrhythmias with a fatal outcome may be induced if there is a deviation below a critical minimum level.
This is likely to be one of the main causes of the sudden cardiac death which frequently occurs in patients with heart failure.
In addition, aldosterone is also thought to be responsible for a number of the myocardial remodeling processes typically to be observed in heart failure. Thus, hyperaldosteronism is a crucial component in the pathogenesis and prognosis of heart failure which may originally be induced by various types of damage such as, for example, a myocardial infarction, a myocardial inflammation or high blood pressure. This assumption is supported by the fact that there was a marked reduction in overall mortality in wide-ranging clinical studies on groups of patients with chronic heart failure and post-myocardial infarction through the use of MRAs [B. Pitt, F. Zannad, W.J. Remme et al., N. Engl. J. Med. 341, 709-717 (1999); B. Pitt, W.
Remme, F. Zannad et al., N. Engl. J. Med. 348, 1309-1321 (2003)]. It was possible to achieve this inter alia by reducing the incidence of sudden cardiac death.
The effects of aldosterone are mediated by the mineralocorticoid receptor which has an intracellular location in the target cells. MRAs available to date, have, like aldosterone itself, a basic steroid structure. The utility of such steroidal antagonists is limited by their interactions with the receptors of other steroid hormones, which in some cases lead to considerable side effects such as gynecomastia and impotence and to discontinuation of the therapy [M.A. Zaman, S. Oparil, D.A. Calhoun, Nature Rev. Drug Disc. 1, 621-636 (2002)].
The use of potent, non-steroidal MRAs which are more selective for the mineralocorticoid receptor provides the possibility of avoiding this profile of side effects and thus achieving a distinct therapeutic advantage.
Moreover, in comparison to the available steroidal MRAs, a non-steroidal structure has at least two important consequences for pharmacological downstream effects:
1.) In contrast to the steroidal MRAs spironolactone and eplerenone, the non-steroidal MRA finerenone is a 'bulky' antagonist (Barfacker et al. 2012). Binding of a 'bulky' non-steroidal MRA probably causes a protrusion of helix 12 in MR's C-terminal-activating function 2 domain, and as a consequence a differential recruitment of transcriptional co-factors in comparison to steroidal MRAs (Amazit et al. J Biol Chem.
2015;290(36):21876-89, Grune et al. J Cardiovasc Pharmacol. 2016;67(5):402-11;
Grune et al.
Hypertension. 2018;71(4):599-608). This specific co-factor recruitment then can lead to a differential gene expression profile in comparison to steroidal MRAs (Grune et al. J Cardiovasc Pharmacol. 2016;67(5):402-11; Grune et al. Hypertension. 2018;71(4):599-608).
This is likely to be one of the main causes of the sudden cardiac death which frequently occurs in patients with heart failure.
In addition, aldosterone is also thought to be responsible for a number of the myocardial remodeling processes typically to be observed in heart failure. Thus, hyperaldosteronism is a crucial component in the pathogenesis and prognosis of heart failure which may originally be induced by various types of damage such as, for example, a myocardial infarction, a myocardial inflammation or high blood pressure. This assumption is supported by the fact that there was a marked reduction in overall mortality in wide-ranging clinical studies on groups of patients with chronic heart failure and post-myocardial infarction through the use of MRAs [B. Pitt, F. Zannad, W.J. Remme et al., N. Engl. J. Med. 341, 709-717 (1999); B. Pitt, W.
Remme, F. Zannad et al., N. Engl. J. Med. 348, 1309-1321 (2003)]. It was possible to achieve this inter alia by reducing the incidence of sudden cardiac death.
The effects of aldosterone are mediated by the mineralocorticoid receptor which has an intracellular location in the target cells. MRAs available to date, have, like aldosterone itself, a basic steroid structure. The utility of such steroidal antagonists is limited by their interactions with the receptors of other steroid hormones, which in some cases lead to considerable side effects such as gynecomastia and impotence and to discontinuation of the therapy [M.A. Zaman, S. Oparil, D.A. Calhoun, Nature Rev. Drug Disc. 1, 621-636 (2002)].
The use of potent, non-steroidal MRAs which are more selective for the mineralocorticoid receptor provides the possibility of avoiding this profile of side effects and thus achieving a distinct therapeutic advantage.
Moreover, in comparison to the available steroidal MRAs, a non-steroidal structure has at least two important consequences for pharmacological downstream effects:
1.) In contrast to the steroidal MRAs spironolactone and eplerenone, the non-steroidal MRA finerenone is a 'bulky' antagonist (Barfacker et al. 2012). Binding of a 'bulky' non-steroidal MRA probably causes a protrusion of helix 12 in MR's C-terminal-activating function 2 domain, and as a consequence a differential recruitment of transcriptional co-factors in comparison to steroidal MRAs (Amazit et al. J Biol Chem.
2015;290(36):21876-89, Grune et al. J Cardiovasc Pharmacol. 2016;67(5):402-11;
Grune et al.
Hypertension. 2018;71(4):599-608). This specific co-factor recruitment then can lead to a differential gene expression profile in comparison to steroidal MRAs (Grune et al. J Cardiovasc Pharmacol. 2016;67(5):402-11; Grune et al. Hypertension. 2018;71(4):599-608).
-5-2.) A non-steroidal chemical structure does not only influence the binding mode within MR, but especially determines the physicochemical properties like lipophilicity and polarity, which have a strong impact on plasma protein binding, transport, tissue penetration and distribution. As an example, the steroidal MRAs are 6- to 10-fold more lipophilic than non-steroidal MRA finerenone, whereas the latter exhibits higher polarity than the steroidal MRAs (Kolkhof et al. Curr Opin Nephrol Hypertens.
2015;24(5):417-24.).
Quantitative wholebody autoradiography with [14C] -labeled finerenone demonstrated a balanced distribution of finerenone into cardiac and kidney tissues of rats, which is in clear contrast to the respective distribution pattern of spironolactone and eplerenone in rodents (Kolkhof et al. J Cardiovasc Pharmacol.
2014;64(1):69-78.). Taken together, structurally different MRAs can lead to a different pharmacology.
Preclinical studies using dystrophin-deficient mice showed that the Angiotensin Conversion Enzyme (ACE) inhibitor lisinopril given in addition to the steroidal MRA spironolactone from 4 to 20 weeks of age is effective in preventing ongoing skeletal muscle damage and significantly improved muscle force generation in both respiratory and limb muscles (Rafael-Fortney et al. Circulation.
2011;124(5):582-588; Lowe et al., J
Neuromuscul Dis. 2016; 3(3): 395-404). Moreover, a randomised, double-blind, placebo-controlled trial in DMD boys demonstrated that addition of the steroidal MRA eplerenone to background ACE inhibitor or Angiotensin Receptor Blocker (ARB) therapy attenuates the progressive decline in left ventricular systolic function as determined by LV circumferential strain (a measure of contractile dysfunction) at 12 months [Raman et al., Lancet Neurology 2015 Feb; 14(2): 1 53-6 1 ].
Accordingly, it is an object of the present invention to provide suitable compounds and compound combinations for use in the treatment and/or prevention of a muscular or neuromuscular disease. Moreover, in order to reduce potential medication burden to pediatric DMD patients, a replacement of two medications such as ACE inhibitor or ARB plus spironolactone or eplerenone (steroidal MRAs) by a single compound is desired.
It was found that non-steroidal MRA monotherapy provides similar structural and functional improvements as observed before with a combination therapy of an ACE inhibitor plus the steroidal MRA spironolactone and can be used for the treatment and/or prevention of a muscular or neuromuscular disease preferably in the treatment and/ or prevention of pediatric population diagnosed with DMD.
Especially preferred in the delay of progression of pediatric population diagnosed with DMD. It was found that non-steroidal mineralocorticoid receptor antagonists in combination with sGC stimulators and/or sGC activators act in a synergistic manner for the treatment and/or prevention of a muscular or neuromuscular disease, such as but not limited to the improvement of muscular functions, e.g. of hearts, striated and non-striated muscles.
According to the current invention the results for Finerenone monotherapie support the use of Finerenone
2015;24(5):417-24.).
Quantitative wholebody autoradiography with [14C] -labeled finerenone demonstrated a balanced distribution of finerenone into cardiac and kidney tissues of rats, which is in clear contrast to the respective distribution pattern of spironolactone and eplerenone in rodents (Kolkhof et al. J Cardiovasc Pharmacol.
2014;64(1):69-78.). Taken together, structurally different MRAs can lead to a different pharmacology.
Preclinical studies using dystrophin-deficient mice showed that the Angiotensin Conversion Enzyme (ACE) inhibitor lisinopril given in addition to the steroidal MRA spironolactone from 4 to 20 weeks of age is effective in preventing ongoing skeletal muscle damage and significantly improved muscle force generation in both respiratory and limb muscles (Rafael-Fortney et al. Circulation.
2011;124(5):582-588; Lowe et al., J
Neuromuscul Dis. 2016; 3(3): 395-404). Moreover, a randomised, double-blind, placebo-controlled trial in DMD boys demonstrated that addition of the steroidal MRA eplerenone to background ACE inhibitor or Angiotensin Receptor Blocker (ARB) therapy attenuates the progressive decline in left ventricular systolic function as determined by LV circumferential strain (a measure of contractile dysfunction) at 12 months [Raman et al., Lancet Neurology 2015 Feb; 14(2): 1 53-6 1 ].
Accordingly, it is an object of the present invention to provide suitable compounds and compound combinations for use in the treatment and/or prevention of a muscular or neuromuscular disease. Moreover, in order to reduce potential medication burden to pediatric DMD patients, a replacement of two medications such as ACE inhibitor or ARB plus spironolactone or eplerenone (steroidal MRAs) by a single compound is desired.
It was found that non-steroidal MRA monotherapy provides similar structural and functional improvements as observed before with a combination therapy of an ACE inhibitor plus the steroidal MRA spironolactone and can be used for the treatment and/or prevention of a muscular or neuromuscular disease preferably in the treatment and/ or prevention of pediatric population diagnosed with DMD.
Especially preferred in the delay of progression of pediatric population diagnosed with DMD. It was found that non-steroidal mineralocorticoid receptor antagonists in combination with sGC stimulators and/or sGC activators act in a synergistic manner for the treatment and/or prevention of a muscular or neuromuscular disease, such as but not limited to the improvement of muscular functions, e.g. of hearts, striated and non-striated muscles.
According to the current invention the results for Finerenone monotherapie support the use of Finerenone
-6-especially for pediatric DMD patients as the burden of medication can be reduced to one single compound.
Definitions The term "muscular or neuromuscular disease" refers to a medical condition that affects the muscles and/or their direct nervous system control. They can be acquired or of genetic origin. In particular, muscular or neuromuscular diseases are characterized for example by Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), Congenital muscular dystrophy, Miyoshi myopathy, Emery¨Dreifuss muscular dystrophy, Facioscapulohumeral muscular dystrophy, Limb-girdle muscular dystrophy, Myotonic muscular dystrophy, Oculopharyngeal muscular dystrophy, Myasthenia gravis, Lambert¨Eaton myasthenic syndrome and Charcot¨Marie¨Tooth disease.
.. Typical symptoms of most forms of muscular or neuromuscular diseases include progressive muscular wasting, poor balance, drooping eyelids, atrophy, scoliosis (curvature of the spine and the back), inability to walk, frequent falls, waddling gait, calf deformation, limited range of movement, respiratory difficulty, joint contractures, cardiomyopathy, arrhythmias and muscle spasms.
The main symptom of Duchenne Muscular Dystrophy (DMD) is muscle weakness associated with muscle wasting with the voluntary muscles being first affected, especially the muscles of the hips, pelvic area, thighs, shoulders, and calf muscles. Muscle weakness also occurs in the arms, neck, and other areas, but not as early as in the lower half of the body. Calves are often enlarged. Symptoms usually appear before age 6 and may appear as early as infancy. Problems with muscles in the upper part of the body (e.g., intercostals and diaphragm) are generally manifested as respiratory difficulties. Other physical symptoms of DMD
include but are not limited to: awkward manner of walking, stepping, or running (patients tend to walk on their forefeet, because of an increased calf tonus; toe walking is a compensatory adaptation to knee extensor weakness); frequent falls; fatigue; difficulty with motor skills (e.g., running, hopping and jumping);
increased lumbar lordosis, leading to shortening of the hip-flexor muscles which has an effect on overall posture and the manner of walking, stepping, or running; muscle contractures of Achilles tendon and hamstrings; impaired functionality because the muscle fibers shorten and fibrosis occurs in connective tissue; progressive difficulty walking; muscle fiber deformities;
pseudohypertrophy or enlarging of tongue and calf muscles (calf enlargement often happens during the ages of 5 to 15, and the muscle tissue is eventually replaced by fat and connective tissue as the legs become less used, hence the term pseudohypertrophy); use of Gower' s maneuver to raise from the floor; higher risk of neurobehavioral .. disorders (e.g., ADHD), learning disorders (dyslexia), and non-progressive weaknesses in specific cognitive skills (in particular short-term verbal memory), which are believed to be the result of absent or dysfunctional dystrophin in the brain; eventual loss of ability to walk (usually by the age of 12); skeletal deformities
Definitions The term "muscular or neuromuscular disease" refers to a medical condition that affects the muscles and/or their direct nervous system control. They can be acquired or of genetic origin. In particular, muscular or neuromuscular diseases are characterized for example by Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), Congenital muscular dystrophy, Miyoshi myopathy, Emery¨Dreifuss muscular dystrophy, Facioscapulohumeral muscular dystrophy, Limb-girdle muscular dystrophy, Myotonic muscular dystrophy, Oculopharyngeal muscular dystrophy, Myasthenia gravis, Lambert¨Eaton myasthenic syndrome and Charcot¨Marie¨Tooth disease.
.. Typical symptoms of most forms of muscular or neuromuscular diseases include progressive muscular wasting, poor balance, drooping eyelids, atrophy, scoliosis (curvature of the spine and the back), inability to walk, frequent falls, waddling gait, calf deformation, limited range of movement, respiratory difficulty, joint contractures, cardiomyopathy, arrhythmias and muscle spasms.
The main symptom of Duchenne Muscular Dystrophy (DMD) is muscle weakness associated with muscle wasting with the voluntary muscles being first affected, especially the muscles of the hips, pelvic area, thighs, shoulders, and calf muscles. Muscle weakness also occurs in the arms, neck, and other areas, but not as early as in the lower half of the body. Calves are often enlarged. Symptoms usually appear before age 6 and may appear as early as infancy. Problems with muscles in the upper part of the body (e.g., intercostals and diaphragm) are generally manifested as respiratory difficulties. Other physical symptoms of DMD
include but are not limited to: awkward manner of walking, stepping, or running (patients tend to walk on their forefeet, because of an increased calf tonus; toe walking is a compensatory adaptation to knee extensor weakness); frequent falls; fatigue; difficulty with motor skills (e.g., running, hopping and jumping);
increased lumbar lordosis, leading to shortening of the hip-flexor muscles which has an effect on overall posture and the manner of walking, stepping, or running; muscle contractures of Achilles tendon and hamstrings; impaired functionality because the muscle fibers shorten and fibrosis occurs in connective tissue; progressive difficulty walking; muscle fiber deformities;
pseudohypertrophy or enlarging of tongue and calf muscles (calf enlargement often happens during the ages of 5 to 15, and the muscle tissue is eventually replaced by fat and connective tissue as the legs become less used, hence the term pseudohypertrophy); use of Gower' s maneuver to raise from the floor; higher risk of neurobehavioral .. disorders (e.g., ADHD), learning disorders (dyslexia), and non-progressive weaknesses in specific cognitive skills (in particular short-term verbal memory), which are believed to be the result of absent or dysfunctional dystrophin in the brain; eventual loss of ability to walk (usually by the age of 12); skeletal deformities
7 (including scoliosis); and cardiomyopathy.
Within the meaning of the present invention, the terms "prevention", "prophylaxis" and "preclusion" are used synonymously in the context of the present invention and refer to the avoidance or reduction of the risk of contracting, experiencing, suffering from or having a disease, a condition, a disorder, an injury or a health problem, or a development or advancement of such states and/or the symptoms of such states.
Within the meaning of the present invention, the terms "treat", "treating" or "treatment" with regard to a disorder or disease refers to alleviating or abrogating the cause and/or effects or symptoms of the disorder or disease. As used herein, the terms "treat", "treatment" and "treating" refer to the reduction or amelioration or slowing down of the progression, severity and/or duration of a muscular and/or neuromuscular disease ( e.g., a Muscular Dystrophy), or the reduction, amelioration or slowing down of the progression, the severity and/or the duration of one or more symptoms (preferably, one or more measurable symptoms) of the condition, as a result of the administration of one or more therapies (e.g., at least one non-steroidal MRA or a pharmaceutically acceptable salt thereof, either alone or in combination with at least one sGC Stimulator.
In some embodiments, the terms "treat," "treatment" and "treating" refer to delaying the onset of a symptom or set of symptoms or to delaying the onset of a loss in certain physical function (e.g., muscular function, walking). In some embodiments, the terms "treat," "treatment" and "treating"
refer to the amelioration of at least one measurable physical parameter of a muscular and/or neuromuscular disease (e.g., a Muscular Dystrophy). In other embodiments the terms "treat", "treatment" and "treating"
refer to the reduction, inhibition or slowing down of the progression of said condition, either physically by, e.g., stabilization of a measurable symptom (e.g., fatigue ), or physiologically by, e.g., stabilization of a measurable parameter (e.g., skeletal Troponin I levels ), or both. As used herein, the term "treating", "treat" or "treatment" also refer to averting the cause and/ or effects of a disease or disorder or one of the symptoms developed as a result of the disease or disorder prior to the disease or disorder fully manifesting itself. The treatment or prevention of a disease, a condition, a disorder, an injury or a health problem may be partial or complete.
Within the meaning of the present invention, the term "sGC activator" refers to molecules that are able to activate heme-free apo sGC. They are defined as NO-independent and heme-independent sGC activators.
Common characteristics of these substances are that in combination with NO
they only have an additive effect on enzyme activation, and that the activation of the oxidized or heme-free enzyme is markedly higher than that of the heme-containing enzyme (Evgenov et al. 2006; Stasch JP et al.
2002; Stasch JP et al. 2006).
Within the meaning of the present invention, the term "non-steroidal mineralocorticoid receptor antagonist"
refers to synthetic, small molecular mineralocorticoid receptor antagonists that are not based on a steroidal, more specifically a sterane or partially unsaturated sterane, chemical structure.
Within the meaning of the present invention, the terms "prevention", "prophylaxis" and "preclusion" are used synonymously in the context of the present invention and refer to the avoidance or reduction of the risk of contracting, experiencing, suffering from or having a disease, a condition, a disorder, an injury or a health problem, or a development or advancement of such states and/or the symptoms of such states.
Within the meaning of the present invention, the terms "treat", "treating" or "treatment" with regard to a disorder or disease refers to alleviating or abrogating the cause and/or effects or symptoms of the disorder or disease. As used herein, the terms "treat", "treatment" and "treating" refer to the reduction or amelioration or slowing down of the progression, severity and/or duration of a muscular and/or neuromuscular disease ( e.g., a Muscular Dystrophy), or the reduction, amelioration or slowing down of the progression, the severity and/or the duration of one or more symptoms (preferably, one or more measurable symptoms) of the condition, as a result of the administration of one or more therapies (e.g., at least one non-steroidal MRA or a pharmaceutically acceptable salt thereof, either alone or in combination with at least one sGC Stimulator.
In some embodiments, the terms "treat," "treatment" and "treating" refer to delaying the onset of a symptom or set of symptoms or to delaying the onset of a loss in certain physical function (e.g., muscular function, walking). In some embodiments, the terms "treat," "treatment" and "treating"
refer to the amelioration of at least one measurable physical parameter of a muscular and/or neuromuscular disease (e.g., a Muscular Dystrophy). In other embodiments the terms "treat", "treatment" and "treating"
refer to the reduction, inhibition or slowing down of the progression of said condition, either physically by, e.g., stabilization of a measurable symptom (e.g., fatigue ), or physiologically by, e.g., stabilization of a measurable parameter (e.g., skeletal Troponin I levels ), or both. As used herein, the term "treating", "treat" or "treatment" also refer to averting the cause and/ or effects of a disease or disorder or one of the symptoms developed as a result of the disease or disorder prior to the disease or disorder fully manifesting itself. The treatment or prevention of a disease, a condition, a disorder, an injury or a health problem may be partial or complete.
Within the meaning of the present invention, the term "sGC activator" refers to molecules that are able to activate heme-free apo sGC. They are defined as NO-independent and heme-independent sGC activators.
Common characteristics of these substances are that in combination with NO
they only have an additive effect on enzyme activation, and that the activation of the oxidized or heme-free enzyme is markedly higher than that of the heme-containing enzyme (Evgenov et al. 2006; Stasch JP et al.
2002; Stasch JP et al. 2006).
Within the meaning of the present invention, the term "non-steroidal mineralocorticoid receptor antagonist"
refers to synthetic, small molecular mineralocorticoid receptor antagonists that are not based on a steroidal, more specifically a sterane or partially unsaturated sterane, chemical structure.
-8-Embodiments One embodiment of the invention is a non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof for use in the treatment and/or prevention of a muscular or neuromuscular disease.
According to a further embodiment, the invention provides non-steroidal MR
Antagonists for use in the treatment and/or prevention of a muscular or neuromuscular disease, wherein the non-steroidal mineralocorticoid receptor antagonist is selected from the group consisting of = (4 S)-4 -(4-cyano-2-methoxypheny1)-5 -ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridine-3-carboxamide, =
1 -(2-hydroxyethyl)-4 -methyl-N-(4-(methylsulfonyl)pheny1)-5 -(2-(trifluoromethyl) pheny1)-1H-pyrrole-3-carboxamide, = N-(4-(4-fluoropheny1)-2,2-dimethy1-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yemethanesulfonamide, = (3 S,3aR)-2 -(3 -Chloro-4-cyanopheny1)-3 -cyclopenty1-3 ,3a,4,5 -tetrahydro-2H-benzo [g] indazole-7 -carboxylic acid, = (R)-6-(1-(4-cyano-3-methylpheny1)-5 -cyclopenty1-4,5 -dihydro-1H-pyrazol-3 -y1)-2 -methoxynicotinic acid, = KBP-5074, = 2-chloro-4-[(3S,3aR)-3 -cyclopenty1-7-(4-hydroxypiperidin-1-carbony1)-3,3a,4,5 -tetrahydro-2H-pyrazolo[3,4-f]quinolin-2-Abenzonitrile, = (S)-N- {3 -[1-cyclopropy1-1-(2,4-difluoro-pheny1)- ethyl] -1H-indo1-7-yll -methanesulfonamide, = SM-368229, = LY2623091, = LY3045697, = MT-3995, = CS-3150 and = AZD9977 or a pharmaceutically acceptable salt thereof.
In another preferred embodiment the non-steroidal MR Antagonist for use in the treatment and/or prevention of a muscular or neuromuscular disease is Finerenone (S)-4-(4-Cyano-2-methoxypheny1)-5-ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridin-3-carboxamid) according to formula (I)
According to a further embodiment, the invention provides non-steroidal MR
Antagonists for use in the treatment and/or prevention of a muscular or neuromuscular disease, wherein the non-steroidal mineralocorticoid receptor antagonist is selected from the group consisting of = (4 S)-4 -(4-cyano-2-methoxypheny1)-5 -ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridine-3-carboxamide, =
1 -(2-hydroxyethyl)-4 -methyl-N-(4-(methylsulfonyl)pheny1)-5 -(2-(trifluoromethyl) pheny1)-1H-pyrrole-3-carboxamide, = N-(4-(4-fluoropheny1)-2,2-dimethy1-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yemethanesulfonamide, = (3 S,3aR)-2 -(3 -Chloro-4-cyanopheny1)-3 -cyclopenty1-3 ,3a,4,5 -tetrahydro-2H-benzo [g] indazole-7 -carboxylic acid, = (R)-6-(1-(4-cyano-3-methylpheny1)-5 -cyclopenty1-4,5 -dihydro-1H-pyrazol-3 -y1)-2 -methoxynicotinic acid, = KBP-5074, = 2-chloro-4-[(3S,3aR)-3 -cyclopenty1-7-(4-hydroxypiperidin-1-carbony1)-3,3a,4,5 -tetrahydro-2H-pyrazolo[3,4-f]quinolin-2-Abenzonitrile, = (S)-N- {3 -[1-cyclopropy1-1-(2,4-difluoro-pheny1)- ethyl] -1H-indo1-7-yll -methanesulfonamide, = SM-368229, = LY2623091, = LY3045697, = MT-3995, = CS-3150 and = AZD9977 or a pharmaceutically acceptable salt thereof.
In another preferred embodiment the non-steroidal MR Antagonist for use in the treatment and/or prevention of a muscular or neuromuscular disease is Finerenone (S)-4-(4-Cyano-2-methoxypheny1)-5-ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridin-3-carboxamid) according to formula (I)
-9-N
OMe Et H
(I) or a pharmaceutically acceptable salt thereof.
One embodiment of the invention is at least one non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof, and at least one more additional therapeutic agent, for use in the treatment of a muscular or neuromuscular disease.
One embodiment of the invention is a pharmaceutical composition comprising at least one non-steroidal MR
Antagonist or a pharmaceutically acceptable salt thereof, and at least one more additional therapeutic agent, for use in the treatment of a muscular or neuromuscular disease.
One embodiment of the invention is at least one non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof in combination with at least one sGC Stimulator for use in the treatment and/or prevention of a muscular or neuromuscular disease.
One embodiment of the invention is at least one non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof in combination with at least one sGC activator for use in the treatment and/or prevention of a muscular or neuromuscular disease.
One embodiment of the invention is a pharmaceutical composition comprising at least one non-steroidal MR
Antagonist or a pharmaceutically acceptable salt thereof in combination with at least one sGC Stimulator for use in the treatment and/or prevention of a muscular or neuromuscular disease.
One embodiment of the invention is a pharmaceutical composition comprising at least one non-steroidal MR
Antagonist or a pharmaceutically acceptable salt thereof in combination with at least one sGC activator for use in the treatment and/or prevention of a muscular or neuromuscular disease.
One embodiment of the invention is a pharmaceutical composition comprising at least one non-steroidal MR
Antagonist in combination with at least one sGC stimulator for use in the treatment and/or prevention of a
OMe Et H
(I) or a pharmaceutically acceptable salt thereof.
One embodiment of the invention is at least one non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof, and at least one more additional therapeutic agent, for use in the treatment of a muscular or neuromuscular disease.
One embodiment of the invention is a pharmaceutical composition comprising at least one non-steroidal MR
Antagonist or a pharmaceutically acceptable salt thereof, and at least one more additional therapeutic agent, for use in the treatment of a muscular or neuromuscular disease.
One embodiment of the invention is at least one non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof in combination with at least one sGC Stimulator for use in the treatment and/or prevention of a muscular or neuromuscular disease.
One embodiment of the invention is at least one non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof in combination with at least one sGC activator for use in the treatment and/or prevention of a muscular or neuromuscular disease.
One embodiment of the invention is a pharmaceutical composition comprising at least one non-steroidal MR
Antagonist or a pharmaceutically acceptable salt thereof in combination with at least one sGC Stimulator for use in the treatment and/or prevention of a muscular or neuromuscular disease.
One embodiment of the invention is a pharmaceutical composition comprising at least one non-steroidal MR
Antagonist or a pharmaceutically acceptable salt thereof in combination with at least one sGC activator for use in the treatment and/or prevention of a muscular or neuromuscular disease.
One embodiment of the invention is a pharmaceutical composition comprising at least one non-steroidal MR
Antagonist in combination with at least one sGC stimulator for use in the treatment and/or prevention of a
-10-muscular or neuromuscular disease, wherein the at least one non-steroidal MR
Antagonist is (S)-4-(4-Cyano-2-methoxypheny1)-5-ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridin- 3-carboxamid according to formula (I) N
OMe Et I N
H
(I), or a pharmaceutically acceptable salt thereof and wherein the at least one sGC
stimulator is selected from the group consisting of:
= 2-[l -(2-fluorob enzy1)-1H-pyrazolo [3,4-b]pyridin-3 -y1]-5 -(4-motpholiny1)-4,6-pyrimidinediamine, = 2-[1-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3-y1]-5-(4-pyridiny1)-4-pyrimidineamine, = methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)-1H-pyrazolo [3,4 -b ]pyridin e-3 -yl]pyrimidin-5 -yll carbamate (Vericiguat, compound of formula (III), known from WO
2011/147809, example 1), = methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)-1H-pyrazolo [3,4 -b ]pyridin e-3 -yl]pyrimidin-5 -yll methylcarbamate, = methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yll (2,2,2-trifluoroethyl)carbamate, = 4-amino-2-[5-chloro-3(3,3,3-trifluoropropy1)-1H-indazol-1-y1]-5,5-dimethy1-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one, = 4-amino-2 [5 -chloro-3 -(2 ,3,6-trifluorobenzy1)-1H-indazol-1 -y1]-5 ,5 -dimethy1-5 ,7 -dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one, = 4-amino-5,5-dimethy1-2- [3 -(2,3,6-trifluorobenzy1)1H-thieno [3 ,4-c]
pyrazol-1 -yl] -5,7-
Antagonist is (S)-4-(4-Cyano-2-methoxypheny1)-5-ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridin- 3-carboxamid according to formula (I) N
OMe Et I N
H
(I), or a pharmaceutically acceptable salt thereof and wherein the at least one sGC
stimulator is selected from the group consisting of:
= 2-[l -(2-fluorob enzy1)-1H-pyrazolo [3,4-b]pyridin-3 -y1]-5 -(4-motpholiny1)-4,6-pyrimidinediamine, = 2-[1-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3-y1]-5-(4-pyridiny1)-4-pyrimidineamine, = methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)-1H-pyrazolo [3,4 -b ]pyridin e-3 -yl]pyrimidin-5 -yll carbamate (Vericiguat, compound of formula (III), known from WO
2011/147809, example 1), = methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)-1H-pyrazolo [3,4 -b ]pyridin e-3 -yl]pyrimidin-5 -yll methylcarbamate, = methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yll (2,2,2-trifluoroethyl)carbamate, = 4-amino-2-[5-chloro-3(3,3,3-trifluoropropy1)-1H-indazol-1-y1]-5,5-dimethy1-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one, = 4-amino-2 [5 -chloro-3 -(2 ,3,6-trifluorobenzy1)-1H-indazol-1 -y1]-5 ,5 -dimethy1-5 ,7 -dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one, = 4-amino-5,5-dimethy1-2- [3 -(2,3,6-trifluorobenzy1)1H-thieno [3 ,4-c]
pyrazol-1 -yl] -5,7-
-11 -dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 4-amino-5,5-dimethy1-2- [3 -(2,3,6-trifluorobenzy1)-1H-thieno [2,3 -d]pyrazol-1 -y1]-5 ,S -dimethy1-5 ,7 -dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 4-amino-5,5-dimethy1-2- [7 -(2,3,646 fluorob enzyl)imidazo [1,5 -b]pyridazin-5 -yl] -5,7 -dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 4-amino-2 - [6-chloro-3 -(2,3 ,6-tri fluorobenzyl)imidazo [1,5 -a]pyridin-1 -yl]] -5,5 -dimethyl-5,7-dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 4-amino-2 - [6-fluoro-3 -(2,3 ,6 -trifluorobenzyl)imidazo [1,5 -a]pyridin-1 -yl]] -5,5 -dimethyl-5,7-dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 4-amino-2 - [6-fluoro-3 -(2,3 ,6 -trifluorobenzy1)6-fluoroimidazo [1,5 -a]pyridin-1 -yl] -5,5 -dimethy1-5 ,7 -dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 4-amino-5,5-dimethy1-2- [3 -(2,4,6-trifluorobenzyl)imidazo [1,5 -a]pyridin-1 -yl]] -5,7-dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 4-amino-2-[3 -(2-cyclop entylethyl)imidazo [1,5 -a]pyridin-1 -yl] -5,5 -dimethy1-5 ,7-dihydro -6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 3 -(4-amino-5 -cyclopropylpyrimidin-2-y1)-1 -(2-fluorobenzy1)-1H-pyrazolo [3,4 -b ]pyridine (BAY 41-2272, compound of formula (II)), r\L,N
.........s...._ m -N
(II), = 2- {5 -fluoro-1 - [(3-fluoropyridin-2-yemethy1]-1H-pyrazolo[3,4-b]pyridin-3-yll -5 -methyl-5 -(trifluoromethyl)-4 - [(3 ,3 ,3 -trifluoropropyl)amino]-5 ,7-dihydro-6H-pyrrolo [2,3 -d]pyrimidin-
.........s...._ m -N
(II), = 2- {5 -fluoro-1 - [(3-fluoropyridin-2-yemethy1]-1H-pyrazolo[3,4-b]pyridin-3-yll -5 -methyl-5 -(trifluoromethyl)-4 - [(3 ,3 ,3 -trifluoropropyl)amino]-5 ,7-dihydro-6H-pyrrolo [2,3 -d]pyrimidin-
-12-6-one, = en t-N- [(2S)-amino-2-methylbuty1]-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer A, compound of formula (IV)), known from WO
2014/068099, example 200), = ent-N-(2-amino-2-methylbuty1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = ent-N-(2-amino-5,5,5-trifluoro-2-methylpenty1)-2,6-dimethy1-8-[(2,3,6-trifluorobenzyl)oxy]imidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = ent-N-(2-amino-5,5,5-trifluoro-2-methylpenty1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = ent-N-(2-amino-5,5,5-trifluoro-2-methylpenty1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer A), = ent-N-(2-amino-3-fluoro-2-methylpropy1)-2,6-dimethy1-8-[(2,3,6-trifluorobenzyl)oxy]imidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = ent-N-(2-amino-3-fluoro-2-methylpropy1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = ent-N-(2-amino-3-fluoro-2-methylpropy1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer A), = rac-N-(2-amino-3-fluoro-2-methylpropy1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide formate, = ent-N-(2-amino-3-fluoro-2-methylpropy1)-2,6-dimethy1-8-[(2,3,6-trifluorobenzyl)oxy]imidazo[1,2-a]pyridine-3-carboxamide (enantiomer A), = ent-N-(2-amino-3-fluoro-2-methylpropy1)-8-[(2,6-difluorobenzyl)oxy]-6-(difluoromethyl)-2-methylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = ent-N-(2-amino-3-fluoro-2-methylpropy1)-8-[(2,6-difluorobenzyl)oxy]-6-(difluoromethyl)-
2014/068099, example 200), = ent-N-(2-amino-2-methylbuty1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = ent-N-(2-amino-5,5,5-trifluoro-2-methylpenty1)-2,6-dimethy1-8-[(2,3,6-trifluorobenzyl)oxy]imidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = ent-N-(2-amino-5,5,5-trifluoro-2-methylpenty1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = ent-N-(2-amino-5,5,5-trifluoro-2-methylpenty1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer A), = ent-N-(2-amino-3-fluoro-2-methylpropy1)-2,6-dimethy1-8-[(2,3,6-trifluorobenzyl)oxy]imidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = ent-N-(2-amino-3-fluoro-2-methylpropy1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = ent-N-(2-amino-3-fluoro-2-methylpropy1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer A), = rac-N-(2-amino-3-fluoro-2-methylpropy1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide formate, = ent-N-(2-amino-3-fluoro-2-methylpropy1)-2,6-dimethy1-8-[(2,3,6-trifluorobenzyl)oxy]imidazo[1,2-a]pyridine-3-carboxamide (enantiomer A), = ent-N-(2-amino-3-fluoro-2-methylpropy1)-8-[(2,6-difluorobenzyl)oxy]-6-(difluoromethyl)-2-methylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = ent-N-(2-amino-3-fluoro-2-methylpropy1)-8-[(2,6-difluorobenzyl)oxy]-6-(difluoromethyl)-
-13-2-methylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer A), = ent-N-(2-amino-3-fluoro-2-methylpropy1)-8-[(2,6-difluorobenzyl)oxy]-6-(fluoromethyl)-2-methylimidazo[1,2-a]pyridine-3-carboxamide, = 1,1,1,3,3,3 -Hexafluoro-2-[( {5 -fluoro-241 -(2-fluorob enzy1)-5 -(1 ,2 -oxazol-3 -y1)-1H-pyrazol-3-y11-4-pyrimidinyllamino)methyll -2-propanol (Praliciguat), = 5 -fluoro-241 -(2-fluorobenzy1)-5 -(1 ,2 -oxazol-3 -y1)-1H-pyrazol-3 -yllpyrimidin-4 -ol (IWP-051), = IWP-121, IWP-427, IWP-953, IW-1701 and IW-6463, or a pharmaceutically acceptable salt thereof.
According to a further embodiment of the present invention, sGC stimulators for use according to the invention are selected from the group consisting of:
= 2-[l -(2-fluorob enzy1)-1H-pyrazolo [3,4-b]pyridin-3 -y1]-5 -(4-motpholiny1)-4,6-pyrimidinediamine, = 2-[1-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3-y1]-5-(4-pyridiny1)-4-pyrimidineamine = methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)-1H-pyrazolo [3,4 -1) ]pyridin e-3 -yl]pyrimidin-5-yll carbamate (Vericiguat, compound of formula (III)), = ent-N-[(2S)-amino-2-methylbuty1]-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer A, compound of formula (IV)), = ent-N-(2-amino-2-methylbuty1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)-1H-pyrazolo [3,4 -1) ]pyridin e-3 -yl]pyrimidin-5 -yll methylcarbamate, = methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yll (2,2,2-trifluoroethyl)carbamate, = 4-amino-2-[5-chloro-3(3,3,3-trifluoropropy1)-1H-indazol-1-y1]-5,5-dimethyl-5,7-dihydro-
According to a further embodiment of the present invention, sGC stimulators for use according to the invention are selected from the group consisting of:
= 2-[l -(2-fluorob enzy1)-1H-pyrazolo [3,4-b]pyridin-3 -y1]-5 -(4-motpholiny1)-4,6-pyrimidinediamine, = 2-[1-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3-y1]-5-(4-pyridiny1)-4-pyrimidineamine = methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)-1H-pyrazolo [3,4 -1) ]pyridin e-3 -yl]pyrimidin-5-yll carbamate (Vericiguat, compound of formula (III)), = ent-N-[(2S)-amino-2-methylbuty1]-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer A, compound of formula (IV)), = ent-N-(2-amino-2-methylbuty1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)-1H-pyrazolo [3,4 -1) ]pyridin e-3 -yl]pyrimidin-5 -yll methylcarbamate, = methyl {4,6-diamino-2-[5-fluoro-1-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yll (2,2,2-trifluoroethyl)carbamate, = 4-amino-2-[5-chloro-3(3,3,3-trifluoropropy1)-1H-indazol-1-y1]-5,5-dimethyl-5,7-dihydro-
- 14-6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 4-amino-2 [5 -chloro-3 -(2,3,6-trifluorobenzy1)- 1 H-indazol- 1 -y1]-5,5 -dimethy1-5,7 -dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 4-amino-5 ,5-dimethy1-2-[3 -(2,3,6-trifluorobenzy1)1H-thieno [3 ,4-c]pyrazol- 1 -y1]-5 ,7 -dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 4-amino-5 ,5-dimethy1-2-[3 -(2,3,6-trifluorob enzy1)- 1 H-thieno [2,3 -d]pyrazol- 1 -y1]-5,5 -dimethy1-5 ,7 -dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 4-amino-5 ,5-dimethy1-2-[7 -(2,3,6-trifluorobenzyl)imidazo [1,5 -b]pyridazin-5 -y1]-5 ,7 -dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 4-amino-2-[6-chloro-3 -(2,3 ,6 -trifluorobenzyl)imidazo [1,5 -a]pyridin-1 -yl]] -5,5 -dimethyl-5,7 -dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 4-amino-2-[6-fluoro-3 -(2,3 ,6-trifluorobenzyl)imidazo [ 1,5 -a]pyridin-1 -yl]] -5,5 -dimethyl-5,7 -dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 4-amino-2-[6-fluoro-3 -(2,3 ,6-trifluorobenzy1)6-fluoroimidazo [1,5 -a]pyridin-1 -y1]-5,5 -dimethy1-5 ,7 -dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 4-amino-5 ,5-dimethy1-2-[3 -(2,4,6-trifluorobenzyl)imidazo [1,5 -a]pyridin-1 -yl]]
dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 4-amino-2-[3 -(2-cyclop entylethyl)imidazo [ 1,5 -a]pyridin- 1 -yl] -5,5 -dimethy1-5 ,7 -dihydro -6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 3 -(4-amino-5 -cyclopropylpyrimidin-2-y1)-1 -(2-fluorobenzy1)- 1H-pyrazolo [3,4 -b ]pyridine, = 2- {5 -fluoro- 1- [(3 -fluoropyridin-2-yemethyl] -1 H-pyrazolo [3,4-b]pyridin-3 -yll -5 -methyl-5 -(trifluoromethyl)-4-[(3 ,3 ,3 -trifluoropropyl)amino]-5 ,7 -dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one and = 1,1,1,3,3,3 -Hexafluoro-2-[( {5 -fluoro-241 -(2-fluorobenzy1)-5 -(1 ,2-oxazol-3 -y1)- 1 H-pyrazol-3 -yl] -4 -pyrimidinyll amino)methyl] -2-propanol (Praliciguat),
dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 4-amino-2-[3 -(2-cyclop entylethyl)imidazo [ 1,5 -a]pyridin- 1 -yl] -5,5 -dimethy1-5 ,7 -dihydro -6H-pyrrolo [2,3 -d]pyrimidin-6-one, = 3 -(4-amino-5 -cyclopropylpyrimidin-2-y1)-1 -(2-fluorobenzy1)- 1H-pyrazolo [3,4 -b ]pyridine, = 2- {5 -fluoro- 1- [(3 -fluoropyridin-2-yemethyl] -1 H-pyrazolo [3,4-b]pyridin-3 -yll -5 -methyl-5 -(trifluoromethyl)-4-[(3 ,3 ,3 -trifluoropropyl)amino]-5 ,7 -dihydro-6H-pyrrolo [2,3 -d]pyrimidin-6-one and = 1,1,1,3,3,3 -Hexafluoro-2-[( {5 -fluoro-241 -(2-fluorobenzy1)-5 -(1 ,2-oxazol-3 -y1)- 1 H-pyrazol-3 -yl] -4 -pyrimidinyll amino)methyl] -2-propanol (Praliciguat),
-15-or a pharmaceutically acceptable salt thereof.
According to a further embodiment of the present invention, sGC stimulators for use according to the invention are selected from the group consisting of:
= 2-[l -(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3 -y1]-5 -(4-moipholiny1)-4,6-pyrimidinediamine, = 2-[1-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3-y1]-5-(4-pyridiny1)-4-pyrimidineamine = methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)- 1 H-pyrazolo [3 ,4 -b ]pyridin e-3 -yl]pyrimidin-5-yll carbamate (Vericiguat, compound of formula (III)), = ent-N-[(2S)-amino-2-methylbuty1]-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer A, compound of formula (IV)), = ent-N-(2-amino-2-methylbuty1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)- 1 H-pyrazolo [3 ,4 -b ]pyridin e-3 -yl]pyrimidin-5 -yll methylcarbamate, = 3 -(4-amino-5 -cyclopropylpyrimidin-2-y1)- 1 -(2-fluorobenzy1)- 1H-pyrazolo [3,4 -b ]pyridine, = 2- {5 -fluoro- 1- [(3 -fluoropyridin-2 -yemethyl] -1 H-pyrazolo [3,4-b]pyridin-3 -yll -5 -methyl-5 -(trifluoromethyl)-4-[(3,3,3-trifluoropropyl)amino]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one and = 1,1,1,3,3,3 -Hexafluoro-2-[( {5 -fluoro-24 1 -(2-fluorobenzy1)-5 -(1 ,2 -oxazol-3 -y1)- 1 H-pyrazol-3-y1]-4-pyrimidinyllamino)methy1]-2-propanol (Praliciguat), or a pharmaceutically acceptable salt thereof.
According to a further embodiment of the present invention, sGC stimulators for use according to the invention are selected from the group consisting of:
= methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)- 1 H-pyrazolo [3 ,4 -b ]pyridin e-3 -yl]pyrimidin-5-yll carbamate (Vericiguat, compound of formula (III)),
According to a further embodiment of the present invention, sGC stimulators for use according to the invention are selected from the group consisting of:
= 2-[l -(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3 -y1]-5 -(4-moipholiny1)-4,6-pyrimidinediamine, = 2-[1-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridin-3-y1]-5-(4-pyridiny1)-4-pyrimidineamine = methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)- 1 H-pyrazolo [3 ,4 -b ]pyridin e-3 -yl]pyrimidin-5-yll carbamate (Vericiguat, compound of formula (III)), = ent-N-[(2S)-amino-2-methylbuty1]-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer A, compound of formula (IV)), = ent-N-(2-amino-2-methylbuty1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)- 1 H-pyrazolo [3 ,4 -b ]pyridin e-3 -yl]pyrimidin-5 -yll methylcarbamate, = 3 -(4-amino-5 -cyclopropylpyrimidin-2-y1)- 1 -(2-fluorobenzy1)- 1H-pyrazolo [3,4 -b ]pyridine, = 2- {5 -fluoro- 1- [(3 -fluoropyridin-2 -yemethyl] -1 H-pyrazolo [3,4-b]pyridin-3 -yll -5 -methyl-5 -(trifluoromethyl)-4-[(3,3,3-trifluoropropyl)amino]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one and = 1,1,1,3,3,3 -Hexafluoro-2-[( {5 -fluoro-24 1 -(2-fluorobenzy1)-5 -(1 ,2 -oxazol-3 -y1)- 1 H-pyrazol-3-y1]-4-pyrimidinyllamino)methy1]-2-propanol (Praliciguat), or a pharmaceutically acceptable salt thereof.
According to a further embodiment of the present invention, sGC stimulators for use according to the invention are selected from the group consisting of:
= methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)- 1 H-pyrazolo [3 ,4 -b ]pyridin e-3 -yl]pyrimidin-5-yll carbamate (Vericiguat, compound of formula (III)),
-16-= ent-N-[(2S)-amino-2-methylbuty1]-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer A, compound of formula (IV)), = ent-N-(2-amino-2-methylbuty1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)-1H-pyrazolo [3,4 -b ]pyridin e-3 -yl]pyrimidin-5 -yll methylcarbamate, = 2- {5 -fluoro-1 - [(3-fluoropyridin-2-yemethy1]-1H-pyrazolo[3,4-b]pyridin-3-yll -5 -methyl-5 -(trifluoromethyl)-4-[(3,3,3-trifluoropropyl)amino]-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one and = 1,1,1,3,3,3 -Hexafluoro-2-[( {5 -fluoro-241 -(2-fluorob enzy1)-5 -(1 ,2 -oxazol-3 -y1)-1H-pyraz ol-3-y1]-4-pyrimidinyllamino)methy1]-2-propanol (Praliciguat), or a pharmaceutically acceptable salt thereof.
According to a further embodiment of the present invention, sGC stimulators for use according to the invention are selected from the group consisting of:
= methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)-1H-pyrazolo [3,4 -b ]pyridin e-3 -yl]pyrimidin-5-yll carbamate (Vericiguat, compound of formula (III)), = ent-N-[(2S)-amino-2-methylbuty1]-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer A, compound of formula (IV)), = ent-N-(2-amino-2-methylbuty1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = 1,1,1,3,3,3 -Hexafluoro-2-[( {5 -fluoro-241 -(2-fluorob enzy1)-5 -(1 ,2 -oxazol-3 -y1)-1H-pyrazol-3-y1]-4-pyrimidinyllamino)methy1]-2-propanol (Praliciguat) and = 3 -(4-amino-5 -cyclopropylpyrimidin-2-y1)-1 -(2-fluorobenzy1)-1H-pyrazolo [3,4 -b ]pyridine (BAY 41-2272, compound of formula (II)) or a pharmaceutically acceptable salt thereof.
According to a further embodiment of the present invention, sGC stimulators for use according to the invention are selected from the group consisting of:
= methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)-1H-pyrazolo [3,4 -b ]pyridin e-3 -yl]pyrimidin-5-yll carbamate (Vericiguat, compound of formula (III)), = ent-N-[(2S)-amino-2-methylbuty1]-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer A, compound of formula (IV)), = ent-N-(2-amino-2-methylbuty1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = 1,1,1,3,3,3 -Hexafluoro-2-[( {5 -fluoro-241 -(2-fluorob enzy1)-5 -(1 ,2 -oxazol-3 -y1)-1H-pyrazol-3-y1]-4-pyrimidinyllamino)methy1]-2-propanol (Praliciguat) and = 3 -(4-amino-5 -cyclopropylpyrimidin-2-y1)-1 -(2-fluorobenzy1)-1H-pyrazolo [3,4 -b ]pyridine (BAY 41-2272, compound of formula (II)) or a pharmaceutically acceptable salt thereof.
17 According to a further embodiment of the present invention, sGC stimulators for use according to the invention are selected from the group consisting of:
= methyl 4,6-diamino-2- [1 -(2-fluorobenzy1)-1H-pyrazolo [3,4-b]
pyridin-3 -yl] -5 -pyrimidinyl(methyl)carbamate (Riociguat), = methyl { 4,6-diamino-2 - [5 -fluoro-1 -(2-fluorobenzy1)- 1H-pyrazolo [3 ,4 -b ]pyridine-3 -yl] pyrimidin-5-y11 carbamate (Vericiguat), = 3-(4-amino-5-cyclopropylpyrimidin-2-y1)-1-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridine (BAY
41-2272) and = 1,1,1,3,3,3 -Hexafluoro-2-[( {5 -fluoro-2 41 -(2-fluorob enzy1)-5 -(1,2 -oxazol-3 -y1)-1H-pyrazol-3 -yl] -4-pyrimidinyllamino)methy1]-2-propanol (Praliciguat) or a pharmaceutically acceptable salt thereof.
According to a further embodiment of the present invention, the sGC
stimulators for use according to the invention is 3 -(4-amino-5 -cyclopropylpyrimidin-2 -y1)-1 -(2-fluorob enzy1)-1H-pyrazolo [3,4 -b ]pyridine (BAY 41-2272) or a pharmaceutically acceptable salt thereof.
A further embodiment of the invention is at least one sGC stimulator selected from the group consisting of = methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)-1H-pyrazolo [3,4 -b ]pyridin e-3 -yl]pyrimidin-5-yll carbamate (Vericiguat, compound of formula (III)), = en t-N-[(2S)-amino-2-methylbuty1]-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer A, compound of formula (IV)), = en t-N-(2-amino-2-methylbuty1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = 1,1,1,3,3,3 -Hexafluoro-2-[( {5 -fluoro-241 -(2-fluorob enzy1)-5 -(1 ,2 -oxazol-3 -y1)-1H-pyrazol-3-y1]-4-pyrimidinyll amino)methy1]-2-propanol (Praliciguat) and = 3 -(4-amino-5 -cyclopropylpyrimidin-2-y1)-1 -(2-fluorobenzy1)-1H-pyrazolo [3,4 -b ]pyridine (BAY 41-2272, compound of formula (II)) or a pharmaceutically acceptable salt thereof in combination with at least one non-steroidal mineralocorticoid receptor antagonist selected from the group
= methyl 4,6-diamino-2- [1 -(2-fluorobenzy1)-1H-pyrazolo [3,4-b]
pyridin-3 -yl] -5 -pyrimidinyl(methyl)carbamate (Riociguat), = methyl { 4,6-diamino-2 - [5 -fluoro-1 -(2-fluorobenzy1)- 1H-pyrazolo [3 ,4 -b ]pyridine-3 -yl] pyrimidin-5-y11 carbamate (Vericiguat), = 3-(4-amino-5-cyclopropylpyrimidin-2-y1)-1-(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridine (BAY
41-2272) and = 1,1,1,3,3,3 -Hexafluoro-2-[( {5 -fluoro-2 41 -(2-fluorob enzy1)-5 -(1,2 -oxazol-3 -y1)-1H-pyrazol-3 -yl] -4-pyrimidinyllamino)methy1]-2-propanol (Praliciguat) or a pharmaceutically acceptable salt thereof.
According to a further embodiment of the present invention, the sGC
stimulators for use according to the invention is 3 -(4-amino-5 -cyclopropylpyrimidin-2 -y1)-1 -(2-fluorob enzy1)-1H-pyrazolo [3,4 -b ]pyridine (BAY 41-2272) or a pharmaceutically acceptable salt thereof.
A further embodiment of the invention is at least one sGC stimulator selected from the group consisting of = methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorob enzy1)-1H-pyrazolo [3,4 -b ]pyridin e-3 -yl]pyrimidin-5-yll carbamate (Vericiguat, compound of formula (III)), = en t-N-[(2S)-amino-2-methylbuty1]-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer A, compound of formula (IV)), = en t-N-(2-amino-2-methylbuty1)-8-[(2,6-difluorobenzyl)oxy]-2,6-dimethylimidazo[1,2-a]pyridine-3-carboxamide (enantiomer B), = 1,1,1,3,3,3 -Hexafluoro-2-[( {5 -fluoro-241 -(2-fluorob enzy1)-5 -(1 ,2 -oxazol-3 -y1)-1H-pyrazol-3-y1]-4-pyrimidinyll amino)methy1]-2-propanol (Praliciguat) and = 3 -(4-amino-5 -cyclopropylpyrimidin-2-y1)-1 -(2-fluorobenzy1)-1H-pyrazolo [3,4 -b ]pyridine (BAY 41-2272, compound of formula (II)) or a pharmaceutically acceptable salt thereof in combination with at least one non-steroidal mineralocorticoid receptor antagonist selected from the group
-18-consisting of = (4 S)-4 -(4-cyano-2-methoxypheny1)-5 -ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridine-3-carboxamide, =
1 -(2-hydroxyethyl)-4 -methyl-N-(4-(methylsulfonyepheny1)-5 -(2-(trifluoromethyl) pheny1)-1 H-pyrrole-3-carboxamide, = N-(4-(4-fluoropheny1)-2,2-dimethy1-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yemethanesulfonamide, = (3 S,3aR)-2 -(3 -Chloro-4-cyanopheny1)-3 -cyclopenty1-3 ,3a,4,5 -tetrahydro-2H-benzo[g]indazole-7-carboxylic acid, = (R)-6-(1-(4-cyano-3-methylpheny1)-5 -cyclopenty1-4,5 -dihydro-1H-pyrazol-3 -y1)-2 -methoxynicotinic acid, = KBP-5074, = 2-chloro-4-[(3S,3aR)-3 -cyclopenty1-7-(4-hydroxypiperidin-1-carbony1)-3,3a,4,5 -tetrahydro-2H
-pyrazolo[3,4-f]quinolin-2-Abenzonitrile, = (S)-N- {3 -[1-cyclopropy1-1-(2,4-difluoro-pheny1)- ethyl] -1H-indo1-7-yll -methanesulfonamide, = SM-368229, = LY2623091, = LY3045697, = MT-3995, = CS-3150 and = AZD9977 or a pharmaceutically acceptable salt thereof for use in the treatment and/or prevention of a muscular or neuromuscular disease.
According to a further embodiment of the present invention, the sGC stimulator for use according to the invention is:
= methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-5-yll carbamate (Vericiguat, compound of formula (III))
1 -(2-hydroxyethyl)-4 -methyl-N-(4-(methylsulfonyepheny1)-5 -(2-(trifluoromethyl) pheny1)-1 H-pyrrole-3-carboxamide, = N-(4-(4-fluoropheny1)-2,2-dimethy1-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-7-yemethanesulfonamide, = (3 S,3aR)-2 -(3 -Chloro-4-cyanopheny1)-3 -cyclopenty1-3 ,3a,4,5 -tetrahydro-2H-benzo[g]indazole-7-carboxylic acid, = (R)-6-(1-(4-cyano-3-methylpheny1)-5 -cyclopenty1-4,5 -dihydro-1H-pyrazol-3 -y1)-2 -methoxynicotinic acid, = KBP-5074, = 2-chloro-4-[(3S,3aR)-3 -cyclopenty1-7-(4-hydroxypiperidin-1-carbony1)-3,3a,4,5 -tetrahydro-2H
-pyrazolo[3,4-f]quinolin-2-Abenzonitrile, = (S)-N- {3 -[1-cyclopropy1-1-(2,4-difluoro-pheny1)- ethyl] -1H-indo1-7-yll -methanesulfonamide, = SM-368229, = LY2623091, = LY3045697, = MT-3995, = CS-3150 and = AZD9977 or a pharmaceutically acceptable salt thereof for use in the treatment and/or prevention of a muscular or neuromuscular disease.
According to a further embodiment of the present invention, the sGC stimulator for use according to the invention is:
= methyl { 4,6-diamino-2- [5 -fluoro-1 -(2-fluorobenzy1)-1H-pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-5-yll carbamate (Vericiguat, compound of formula (III))
-19-F
*
N N
1 *NI
F
---N
1\1\µ )___N
N/---f 0 N,f 0, (III), or a pharmaceutically acceptable salt thereof.
According to a further embodiment of the present invention, the sGC stimulator for use according to the invention is:
= ent-N-[(2S)-amino-2-methylbutyl] -8 -[(2,6-difluorobenzyl)oxy] -2,6 -dimethylimidazo [1 ,2-a]pyridine-3-carboxamide (enantiomer A) (compound of formula (IV)) 'F
H3cZ----;..¨CI-Nr.1.....H
H
H
(IV), or a pharmaceutically acceptable salt thereof.
One embodiment of the invention is at least one non-steroidal MR Antagonist in combination with at least one sGC activator for use in the treatment and/or prevention of a muscular or neuromuscular disease.
One embodiment of the invention is a pharmaceutical composition comprising at least one non-steroidal MR
Antagonist in combination with at least one sGC activator for use in the treatment and/or prevention of a muscular or neuromuscular disease.
One embodiment of the invention is a pharmaceutical composition comprising at least one non-steroidal MR
Antagonist in combination with at least one sGC activator for use in the treatment and/or prevention of a muscular or neuromuscular disease, wherein the at least one non-steroidal mineralocorticoid receptor
*
N N
1 *NI
F
---N
1\1\µ )___N
N/---f 0 N,f 0, (III), or a pharmaceutically acceptable salt thereof.
According to a further embodiment of the present invention, the sGC stimulator for use according to the invention is:
= ent-N-[(2S)-amino-2-methylbutyl] -8 -[(2,6-difluorobenzyl)oxy] -2,6 -dimethylimidazo [1 ,2-a]pyridine-3-carboxamide (enantiomer A) (compound of formula (IV)) 'F
H3cZ----;..¨CI-Nr.1.....H
H
H
(IV), or a pharmaceutically acceptable salt thereof.
One embodiment of the invention is at least one non-steroidal MR Antagonist in combination with at least one sGC activator for use in the treatment and/or prevention of a muscular or neuromuscular disease.
One embodiment of the invention is a pharmaceutical composition comprising at least one non-steroidal MR
Antagonist in combination with at least one sGC activator for use in the treatment and/or prevention of a muscular or neuromuscular disease.
One embodiment of the invention is a pharmaceutical composition comprising at least one non-steroidal MR
Antagonist in combination with at least one sGC activator for use in the treatment and/or prevention of a muscular or neuromuscular disease, wherein the at least one non-steroidal mineralocorticoid receptor
-20-antagonist is (S)-4-(4-Cyano-2-methoxypheny1)-5-ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridin- 3-carboxamid according to formula (I) N
OMe Et I N
H
(I) or a pharmaceutically acceptable salt thereof and wherein the at least on sGC
activator is selected from the group consisting of = 4-( {(4-carboxybuty1)[2-(2- { [4-(2-phenylethyl)b enzyl] oxy}
phenyeethyllamino } methyl)benzoic acid;
(INN: Cinaciguat), = 5-chloro-2-(5-chlorothiophene-2-sulfonylamino-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide as sodium salt, = 2-(4-chlorophenylsulfonylamino)-4,5 -dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)phenyl)benzamide, = 1- {645 -chloro-2-( {4-trans-4-}trifluoromethyl)cyclohexyllbenzyll oxy)phenyl]pyridin-2-yll -5 -(trifluoromethyl)-1H-pyrazole-4-carboxylic acid, = 1-[6-(2-(2-methy1-4-(4-trifluoromethoxyphenyl)benzyloxy)phenyl)pyridin-2-y1]-5-trifluoromethylpyrazole-4-carboxylic acid, = 1[6-(3,4-dichloropheny1)-2-pyridiny1-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid = 1-( {2- [3 -chloro-5 -(trifluoromethyl)phenyl] -5 -methyl-1,3 -thiazol-4-yll methyl)-1 H-pyrazole-4-carboxylic acid, = 4-( {2- [3 -(trifluoromethyl)phenyl] -1,3 -thiazol-4 -yll methyl)benzoic acid = 1 -( {2- [2-fluoro-3 -(trifluoromethyl)pheny1]-5 -methyl-1,3 -thiazol-4 -yll methyl)-1 H-pyrazole-4-carboxylic acid, = 3-(4-chloro-3-{[(2S,3R)-2-(4-chloropheny1)-4,4,4-trifluoro-3-methylbutanoyllaminolpheny1)-3-cyclopropylpropanoic acid, = 5- { [2-(4-carboxyphenyeethyl] [2-(2-{ [3-chloro-4'-(trifluoromethyl)bipheny1-4-yl]methoxylphenyl)ethyllaminol-5,6,7,8-tetrahydroquinoline-2-carboxylic acid, = 5- {(4-carb oxybutyl) [2-(2- { [3 -chloro-4'-(trifluoromethyl)bipheny1-4 -
OMe Et I N
H
(I) or a pharmaceutically acceptable salt thereof and wherein the at least on sGC
activator is selected from the group consisting of = 4-( {(4-carboxybuty1)[2-(2- { [4-(2-phenylethyl)b enzyl] oxy}
phenyeethyllamino } methyl)benzoic acid;
(INN: Cinaciguat), = 5-chloro-2-(5-chlorothiophene-2-sulfonylamino-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide as sodium salt, = 2-(4-chlorophenylsulfonylamino)-4,5 -dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)phenyl)benzamide, = 1- {645 -chloro-2-( {4-trans-4-}trifluoromethyl)cyclohexyllbenzyll oxy)phenyl]pyridin-2-yll -5 -(trifluoromethyl)-1H-pyrazole-4-carboxylic acid, = 1-[6-(2-(2-methy1-4-(4-trifluoromethoxyphenyl)benzyloxy)phenyl)pyridin-2-y1]-5-trifluoromethylpyrazole-4-carboxylic acid, = 1[6-(3,4-dichloropheny1)-2-pyridiny1-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid = 1-( {2- [3 -chloro-5 -(trifluoromethyl)phenyl] -5 -methyl-1,3 -thiazol-4-yll methyl)-1 H-pyrazole-4-carboxylic acid, = 4-( {2- [3 -(trifluoromethyl)phenyl] -1,3 -thiazol-4 -yll methyl)benzoic acid = 1 -( {2- [2-fluoro-3 -(trifluoromethyl)pheny1]-5 -methyl-1,3 -thiazol-4 -yll methyl)-1 H-pyrazole-4-carboxylic acid, = 3-(4-chloro-3-{[(2S,3R)-2-(4-chloropheny1)-4,4,4-trifluoro-3-methylbutanoyllaminolpheny1)-3-cyclopropylpropanoic acid, = 5- { [2-(4-carboxyphenyeethyl] [2-(2-{ [3-chloro-4'-(trifluoromethyl)bipheny1-4-yl]methoxylphenyl)ethyllaminol-5,6,7,8-tetrahydroquinoline-2-carboxylic acid, = 5- {(4-carb oxybutyl) [2-(2- { [3 -chloro-4'-(trifluoromethyl)bipheny1-4 -
-21-yl]methoxyl phenyl)ethyl]amino 1 -5,6,7,8 -tetrahydroquinoline-2 -carboxylic acid, = (1R,5S)-3- [4-(5 -methyl-2- { [2-methy1-4-(piperidin-1-ylcarbonyl)benzyl]
oxylpheny1)-1,3 -thiazol-2-y1]-3-azabicyclo[3.2.1]octane-8-carboxylic acid, = 1- [6-(5 -methyl-2- { [2-(tetrahydro-2H-pyran-4-y1)-1,2,3,4-tetrahydroisoquinolin-6-yl]methoxy } phenyl)pyridin-2-yl] -5 -(trifluoromethyl)-1H-pyrazole-4-carboxylic acid, = BI-703704 and = BI-684067 or a pharmaceutically acceptable salt thereof.
A further embodiment of the invention is a pharmaceutical composition comprising at least one non-steroidal MR Antagonist in combination with at least one sGC activator for use in the treatment and/or prevention of a muscular or neuromuscular disease, wherein the at least one non-steroidal mineralocorticoid receptor antagonist is (S)-4-(4-Cyano-2-methoxypheny1)-5-ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridin-3-carboxamid according to formula (I) N
OMe Et I N
H
(I) or a pharmaceutically acceptable salt thereof and wherein the at least on sGC
activator is selected from the group consisting of = 3 -(4-chloro-3 - { [(2S,3R)-2-(4-chloropheny1)-4,4,4-tri flu oro-3 -methylbutanoyl] amino } pheny1)-3-cyclopropylpropanoic acid, = 5- { [2-(4-carboxyphenyl)ethyl] [2-(2-{ [3-chloro-4'-(trifluoromethyl)bipheny1-4-yl]methoxyl phenyl)ethyl]amino } -5,6,7,8 -tetrahydroquinoline-2 -carboxylic acid, = 5- {(4-carb oxybutyl) [2-(2- { [3 -chloro-4'-(trifluoromethyl)bipheny1-4 -yl]methoxy } phenyl)ethyl]amino } -5,6,7,8 -tetrahydroquinoline-2 -carboxylic acid, or a pharmaceutically acceptable salt thereof.
oxylpheny1)-1,3 -thiazol-2-y1]-3-azabicyclo[3.2.1]octane-8-carboxylic acid, = 1- [6-(5 -methyl-2- { [2-(tetrahydro-2H-pyran-4-y1)-1,2,3,4-tetrahydroisoquinolin-6-yl]methoxy } phenyl)pyridin-2-yl] -5 -(trifluoromethyl)-1H-pyrazole-4-carboxylic acid, = BI-703704 and = BI-684067 or a pharmaceutically acceptable salt thereof.
A further embodiment of the invention is a pharmaceutical composition comprising at least one non-steroidal MR Antagonist in combination with at least one sGC activator for use in the treatment and/or prevention of a muscular or neuromuscular disease, wherein the at least one non-steroidal mineralocorticoid receptor antagonist is (S)-4-(4-Cyano-2-methoxypheny1)-5-ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridin-3-carboxamid according to formula (I) N
OMe Et I N
H
(I) or a pharmaceutically acceptable salt thereof and wherein the at least on sGC
activator is selected from the group consisting of = 3 -(4-chloro-3 - { [(2S,3R)-2-(4-chloropheny1)-4,4,4-tri flu oro-3 -methylbutanoyl] amino } pheny1)-3-cyclopropylpropanoic acid, = 5- { [2-(4-carboxyphenyl)ethyl] [2-(2-{ [3-chloro-4'-(trifluoromethyl)bipheny1-4-yl]methoxyl phenyl)ethyl]amino } -5,6,7,8 -tetrahydroquinoline-2 -carboxylic acid, = 5- {(4-carb oxybutyl) [2-(2- { [3 -chloro-4'-(trifluoromethyl)bipheny1-4 -yl]methoxy } phenyl)ethyl]amino } -5,6,7,8 -tetrahydroquinoline-2 -carboxylic acid, or a pharmaceutically acceptable salt thereof.
-22-A further embodiment of the invention is a pharmaceutical composition comprising at least one sGC
activator selected from the group consisting of = 3-(4-chloro-3-{[(2S,3R)-2-(4-chloropheny1)-4,4,4-trifluoro-3-methylbutanoyllaminolpheny1)-3-cyclopropylpropanoic acid, = 5- {[2-(4-carboxyphenyeethyl][2-(2-{ [3-chloro-4'-(trifluoromethyl)bipheny1-4-Amethoxylphenyl)ethyllaminol -5,6,7,8-tetrahydroquinoline-2-carboxylic acid and = 5- {(4-carb oxybutyl) [2-(2- { [3 -chloro-4'-(trifluoromethyl)bipheny1-4-Amethoxylphenyl)ethyllaminol -5,6,7,8-tetrahydroquinoline-2-carboxylic acid or a pharmaceutically acceptable salt thereof in combination with at least one non-steroidal MR Antagonist selected from the group consisting of = (4 S)-4 -(4-cyano-2-methoxypheny1)-5 -ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridine-3-carboxamide, = 1 -(2-hydroxyethyl)-4 -methyl-N-(4-(methylsulfonyl)pheny1)-5 -(2-(trifluoromethyl) pheny1)-1H-pyrrole-3-carboxamide, = N-(4-(4-fluoropheny1)-2,2-dimethy1-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-yemethanesulfonamide, = (3 S,3aR)-2 -(3 -Chloro-4-cyanopheny1)-3 -cyclopenty1-3 ,3a,4,5 -tetrahydro-2H-benzo [g] indazole-7 -carboxylic acid, = (R)-6-(1-(4-cyano-3-methylpheny1)-5 -cyclopenty1-4,5 -dihydro-1H-pyrazol-3 -y1)-2 -methoxynicotinic acid, = KBP-5074, = 2-chloro-4-[(3S,3aR)-3 -cyclopenty1-7-(4-hydroxypiperidin-1-carbony1)-3,3a,4,5 -tetrahydro-2H
-pyrazolo[3,4-f]quinolin-2-Abenzonitrile, = (S)-N- {3 -[1-cyclopropy1-1-(2,4-difluoro-pheny1)- ethyl] -1H-indo1-7-yll -methanesulfonamide, = SM-368229, = LY2623091, = LY3045697, = MT-3995, = CS-3150 and = AZD9977 or a pharmaceutically acceptable salt thereof for use in the treatment and/or prevention of a muscular or
activator selected from the group consisting of = 3-(4-chloro-3-{[(2S,3R)-2-(4-chloropheny1)-4,4,4-trifluoro-3-methylbutanoyllaminolpheny1)-3-cyclopropylpropanoic acid, = 5- {[2-(4-carboxyphenyeethyl][2-(2-{ [3-chloro-4'-(trifluoromethyl)bipheny1-4-Amethoxylphenyl)ethyllaminol -5,6,7,8-tetrahydroquinoline-2-carboxylic acid and = 5- {(4-carb oxybutyl) [2-(2- { [3 -chloro-4'-(trifluoromethyl)bipheny1-4-Amethoxylphenyl)ethyllaminol -5,6,7,8-tetrahydroquinoline-2-carboxylic acid or a pharmaceutically acceptable salt thereof in combination with at least one non-steroidal MR Antagonist selected from the group consisting of = (4 S)-4 -(4-cyano-2-methoxypheny1)-5 -ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridine-3-carboxamide, = 1 -(2-hydroxyethyl)-4 -methyl-N-(4-(methylsulfonyl)pheny1)-5 -(2-(trifluoromethyl) pheny1)-1H-pyrrole-3-carboxamide, = N-(4-(4-fluoropheny1)-2,2-dimethy1-3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-yemethanesulfonamide, = (3 S,3aR)-2 -(3 -Chloro-4-cyanopheny1)-3 -cyclopenty1-3 ,3a,4,5 -tetrahydro-2H-benzo [g] indazole-7 -carboxylic acid, = (R)-6-(1-(4-cyano-3-methylpheny1)-5 -cyclopenty1-4,5 -dihydro-1H-pyrazol-3 -y1)-2 -methoxynicotinic acid, = KBP-5074, = 2-chloro-4-[(3S,3aR)-3 -cyclopenty1-7-(4-hydroxypiperidin-1-carbony1)-3,3a,4,5 -tetrahydro-2H
-pyrazolo[3,4-f]quinolin-2-Abenzonitrile, = (S)-N- {3 -[1-cyclopropy1-1-(2,4-difluoro-pheny1)- ethyl] -1H-indo1-7-yll -methanesulfonamide, = SM-368229, = LY2623091, = LY3045697, = MT-3995, = CS-3150 and = AZD9977 or a pharmaceutically acceptable salt thereof for use in the treatment and/or prevention of a muscular or
-23-neuromuscular disease.
One embodiment of the invention is a pharmaceutical composition comprising at least one sGC activator in combination with at least one non-steroidal MR Antagonist for use in the treatment and/or prevention of a muscular or neuromuscular disease, wherein the at least one sGC activator is 3-(4-chloro-3- { [(2S,3R)-2-(4-chloropheny1)-4,4,4 -trifluoro-3 -methylbutanoyl] amino 1 pheny1)-3-cyclopropylpropanoic acid or a pharmaceutically acceptable salt thereof and the at least one non-steroidal MR
Antagonist is (S)-4-(4-Cyano-2-methoxypheny1)-5-ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridin- 3 -carboxamid according to formula (I) or a pharmaceutically acceptable salt thereof.
One embodiment of the invention is a medicament, comprising a non-steroidal MR
Antagonist or a pharmaceutically acceptable salt thereof in combination with one or more inert non-toxic pharmaceutically suitable auxiliaries for use in the treatment and/or prevention of a muscular or neuromuscular disease.
One embodiment of the invention is a medicament, comprising a pharmaceutical composition according to the current invention in combination with one or more inert non-toxic pharmaceutically suitable auxiliaries for use in the treatment and/or prevention of a muscular or neuromuscular disease.
One embodiment of the invention is a method for the treatment and/or prevention of a muscular or neuromuscular disease in humans and animals by administration of an effective amount of at least one non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof or of a medicament comprising a non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof in combination with one or more inert non-toxic pharmaceutically suitable auxiliaries.
One embodiment of the invention is a method for the treatment and/or prevention of a muscular or neuromuscular disease in humans and animals by administration of an effective amount of a pharmaceutical composition comprising a non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof, and at least one more additional therapeutic agent or of a medicament comprising a pharmaceutical composition in combination with one or more inert non-toxic pharmaceutically suitable auxiliaries.
Within the meaning of the aforementioned embodiments the at least one more additional therapeutic agent is preferably a sGC stimulator or a sGC activator as defined above.
Within the meaning of the aforementioned embodiments, the term "muscular or neuromuscular disease"
refers to a group of medical conditions consisting of Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), Congenital muscular dystrophy, Miyoshi myopathy, Emery¨Dreifuss muscular dystrophy , Facioscapulohumeral muscular dystrophy, Limb-girdle muscular dystrophy, Myotonic muscular
One embodiment of the invention is a pharmaceutical composition comprising at least one sGC activator in combination with at least one non-steroidal MR Antagonist for use in the treatment and/or prevention of a muscular or neuromuscular disease, wherein the at least one sGC activator is 3-(4-chloro-3- { [(2S,3R)-2-(4-chloropheny1)-4,4,4 -trifluoro-3 -methylbutanoyl] amino 1 pheny1)-3-cyclopropylpropanoic acid or a pharmaceutically acceptable salt thereof and the at least one non-steroidal MR
Antagonist is (S)-4-(4-Cyano-2-methoxypheny1)-5-ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridin- 3 -carboxamid according to formula (I) or a pharmaceutically acceptable salt thereof.
One embodiment of the invention is a medicament, comprising a non-steroidal MR
Antagonist or a pharmaceutically acceptable salt thereof in combination with one or more inert non-toxic pharmaceutically suitable auxiliaries for use in the treatment and/or prevention of a muscular or neuromuscular disease.
One embodiment of the invention is a medicament, comprising a pharmaceutical composition according to the current invention in combination with one or more inert non-toxic pharmaceutically suitable auxiliaries for use in the treatment and/or prevention of a muscular or neuromuscular disease.
One embodiment of the invention is a method for the treatment and/or prevention of a muscular or neuromuscular disease in humans and animals by administration of an effective amount of at least one non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof or of a medicament comprising a non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof in combination with one or more inert non-toxic pharmaceutically suitable auxiliaries.
One embodiment of the invention is a method for the treatment and/or prevention of a muscular or neuromuscular disease in humans and animals by administration of an effective amount of a pharmaceutical composition comprising a non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof, and at least one more additional therapeutic agent or of a medicament comprising a pharmaceutical composition in combination with one or more inert non-toxic pharmaceutically suitable auxiliaries.
Within the meaning of the aforementioned embodiments the at least one more additional therapeutic agent is preferably a sGC stimulator or a sGC activator as defined above.
Within the meaning of the aforementioned embodiments, the term "muscular or neuromuscular disease"
refers to a group of medical conditions consisting of Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), Congenital muscular dystrophy, Miyoshi myopathy, Emery¨Dreifuss muscular dystrophy , Facioscapulohumeral muscular dystrophy, Limb-girdle muscular dystrophy, Myotonic muscular
-24-dystrophy, Oculopharyngeal muscular dystrophy, Myasthenia gravis, Lambert¨Eaton myasthenic syndrome and Charcot¨Marie¨Tooth disease.
Within the meaning of the aforementioned embodiments, the term "muscular or neuromuscular disease"
preferably is a muscular dystrophy, especially preferred Duchenne muscular dystrophy (DMD).
We identified non-steroidal MRAs for the treatment and/or prevention of muscular or neuromuscular disease.
We identified (S)-4-(4-Cyano-2-methoxypheny1)-5-ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridin-3-carboxamid according to formula (I) or a pharmaceutically acceptable salt thereof for the treatment and/or prevention of muscular or neuromuscular disease. Surprisingly (S)-4-(4-Cyano-2-methoxypheny1)-5-ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridin-3-carboxamid according to formula (I) or a pharmaceutically acceptable salt thereof as monotherapy is as effective as a combination of the steroidal MR
antagonist spironolactone and the ACE inhibitor lisinopril regarding measurements of grip strength, in base myocardial strain rate, and in improved forces after lengthening contractions of the extensor digitorum longus.
We further identified combinations of non-steroidal mineralocorticoid receptor antagonists in combination with sGC stimulators for the treatment and/or prevention of muscular or neuromuscular disease with synergistic efficacy compared to sGC stimulators or non-steroidal mineralocorticoid receptor antagonists alone. Synergic effects can be found regarding formation of fibrotic tissue, gene expression, heart and muscle damage, muscle function, heart and cardiovascular function, muscle force and/or physical capacity.
We further identified combinations of non-steroidal mineralocorticoid receptor antagonists in combination with sGC activators for the treatment and/or prevention of muscular or neuromuscular disease with synergistic efficacy compared to sGC activators or non-steroidal mineralocorticoid receptor antagonists alone. Synergic effects can be found regarding formation of fibrotic tissue, gene expression, heart and muscle damage, muscle function, heart and cardiovascular function, muscle force and/or physical capacity.
In a combination of sGC stimulators and non-steroidal mineralocorticoid receptor antagonists dosages of the compounds are surprisingly lower compared to sGC stimulators and mineralocorticoid receptor antagonists alone.
In a combination of sGC activators and non-steroidal mineralocorticoid receptor antagonists dosages of the compounds are surprisingly lower compared to sGC activators and mineralocorticoid receptor antagonists alone.
Within the meaning of the aforementioned embodiments, the term "muscular or neuromuscular disease"
preferably is a muscular dystrophy, especially preferred Duchenne muscular dystrophy (DMD).
We identified non-steroidal MRAs for the treatment and/or prevention of muscular or neuromuscular disease.
We identified (S)-4-(4-Cyano-2-methoxypheny1)-5-ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridin-3-carboxamid according to formula (I) or a pharmaceutically acceptable salt thereof for the treatment and/or prevention of muscular or neuromuscular disease. Surprisingly (S)-4-(4-Cyano-2-methoxypheny1)-5-ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridin-3-carboxamid according to formula (I) or a pharmaceutically acceptable salt thereof as monotherapy is as effective as a combination of the steroidal MR
antagonist spironolactone and the ACE inhibitor lisinopril regarding measurements of grip strength, in base myocardial strain rate, and in improved forces after lengthening contractions of the extensor digitorum longus.
We further identified combinations of non-steroidal mineralocorticoid receptor antagonists in combination with sGC stimulators for the treatment and/or prevention of muscular or neuromuscular disease with synergistic efficacy compared to sGC stimulators or non-steroidal mineralocorticoid receptor antagonists alone. Synergic effects can be found regarding formation of fibrotic tissue, gene expression, heart and muscle damage, muscle function, heart and cardiovascular function, muscle force and/or physical capacity.
We further identified combinations of non-steroidal mineralocorticoid receptor antagonists in combination with sGC activators for the treatment and/or prevention of muscular or neuromuscular disease with synergistic efficacy compared to sGC activators or non-steroidal mineralocorticoid receptor antagonists alone. Synergic effects can be found regarding formation of fibrotic tissue, gene expression, heart and muscle damage, muscle function, heart and cardiovascular function, muscle force and/or physical capacity.
In a combination of sGC stimulators and non-steroidal mineralocorticoid receptor antagonists dosages of the compounds are surprisingly lower compared to sGC stimulators and mineralocorticoid receptor antagonists alone.
In a combination of sGC activators and non-steroidal mineralocorticoid receptor antagonists dosages of the compounds are surprisingly lower compared to sGC activators and mineralocorticoid receptor antagonists alone.
-25-The present invention further provides medicaments which comprise at least one compound or a combination of compounds according to the invention, typically together with one or more inert, nontoxic, pharmaceutically suitable auxiliaries, and the use thereof for the aforementioned purposes.
The compounds, combinations, pharmaceutical compositions and medicaments according to the invention may act systemically and/or locally. For this purpose, they can be administered in a suitable manner, for example by the oral, parenteral, pulmonal, nasal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctival, otic route, or as an implant or stent.
The compounds, combinations, pharmaceutical compositions and medicaments according to the invention can be administered in administration forms suitable for these administration routes.
Suitable administration forms for oral administration are those which work according to the prior art, which release the compounds, combinations, pharmaceutical compositions and medicaments according to the invention rapidly and/or in a modified manner and which contain the compounds according to the invention in crystalline and/or amorphized and/or dissolved form, for example tablets (uncoated or coated tablets, for example with gastric juice-resistant or retarded-dissolution or insoluble coatings which control the release of the compound according to the invention), tablets or films/wafers which disintegrate rapidly in the oral cavity, films/lyophilizates or capsules (for example hard or soft gelatin capsules), sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions.
Parenteral administration can bypass an absorption step (e.g. intravenously, intraarterially, intracardially, intraspinally or intralumbally) or include an absorption (e.g.
intramuscularly, subcutaneously, intracutaneously, percutaneously or intraperitoneally). Administration forms suitable for parenteral administration include preparations for injection and infusion in the form of solutions, suspensions, emulsions, lyophilizates or sterile powders.
For the other administration routes, suitable examples are inhalable medicament forms (including powder inhalers, nebulizers), nasal drops, solutions or sprays, tablets, films/wafers or capsules for lingual, sublingual or buccal administration, suppositories, ear or eye preparations, vaginal capsules, aqueous suspensions (lotions, shaking mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (e.g. patches), milk, pastes, foams, sprinkling powders, implants or stents.
Oral or parenteral administration is preferred, especially oral and intravenous administration.
The compounds, combinations, pharmaceutical compositions and medicaments according to the invention can be converted to the administration forms mentioned. This can be done in a manner known per se, by
The compounds, combinations, pharmaceutical compositions and medicaments according to the invention may act systemically and/or locally. For this purpose, they can be administered in a suitable manner, for example by the oral, parenteral, pulmonal, nasal, sublingual, lingual, buccal, rectal, dermal, transdermal, conjunctival, otic route, or as an implant or stent.
The compounds, combinations, pharmaceutical compositions and medicaments according to the invention can be administered in administration forms suitable for these administration routes.
Suitable administration forms for oral administration are those which work according to the prior art, which release the compounds, combinations, pharmaceutical compositions and medicaments according to the invention rapidly and/or in a modified manner and which contain the compounds according to the invention in crystalline and/or amorphized and/or dissolved form, for example tablets (uncoated or coated tablets, for example with gastric juice-resistant or retarded-dissolution or insoluble coatings which control the release of the compound according to the invention), tablets or films/wafers which disintegrate rapidly in the oral cavity, films/lyophilizates or capsules (for example hard or soft gelatin capsules), sugar-coated tablets, granules, pellets, powders, emulsions, suspensions, aerosols or solutions.
Parenteral administration can bypass an absorption step (e.g. intravenously, intraarterially, intracardially, intraspinally or intralumbally) or include an absorption (e.g.
intramuscularly, subcutaneously, intracutaneously, percutaneously or intraperitoneally). Administration forms suitable for parenteral administration include preparations for injection and infusion in the form of solutions, suspensions, emulsions, lyophilizates or sterile powders.
For the other administration routes, suitable examples are inhalable medicament forms (including powder inhalers, nebulizers), nasal drops, solutions or sprays, tablets, films/wafers or capsules for lingual, sublingual or buccal administration, suppositories, ear or eye preparations, vaginal capsules, aqueous suspensions (lotions, shaking mixtures), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (e.g. patches), milk, pastes, foams, sprinkling powders, implants or stents.
Oral or parenteral administration is preferred, especially oral and intravenous administration.
The compounds, combinations, pharmaceutical compositions and medicaments according to the invention can be converted to the administration forms mentioned. This can be done in a manner known per se, by
-26-mixing with inert, nontoxic, pharmaceutically suitable excipients. These excipients include carriers (for example microcrystalline cellulose, lactose, mannitol), solvents (e.g. liquid polyethylene glycols), emulsifiers and dispersing or wetting agents (for example sodium dodecylsulphate, polyoxysorbitan oleate), binders (for example polyvinylpyrrolidone), synthetic and natural polymers (for example albumin), stabilizers (e.g. antioxidants, for example ascorbic acid), dyes (e.g.
inorganic pigments, for example iron oxides) and flavour and/or odour correctants.
In general, it has been found to be advantageous in the case of parenteral administration to administer amounts of about 0.001 to 1 mg/kg, preferably about 0.01 to 0.5 mg/kg, of body weight to achieve effective results. In the case of oral administration, the dosage is about 0.01 to 100 mg/kg, preferably about 0.01 to 20 mg/kg and most preferably 0.1 to 10 mg/kg of body weight.
For Finerenone administration in the pediatric population a dose of 5 to 40 mg, preferably 10 to 20 mg once daily for children with body weights in the adult range (approximatel 70 to 80kg) is the preferred dosage range.
For children with lower body weights (below 70 to 80 kg) a dose range will be calculated to achieve a similar exposure as observed in adults treated with doses of 5 to 40 mg respectively 10 to 20 mg once daily.
(Edginton AN, Schmitt W, Willmann S. Clin Pharmacokinet. 2006;45(10) :1013 -34).
It may nevertheless be necessary where appropriate to deviate from the stated amounts, specifically as a function of the body weight, route of administration, individual response to the active compound, nature of the preparation and time or interval over which administration takes place.
For instance, in some cases, less than the aforementioned minimum amount may be sufficient, while in other cases the upper limit mentioned must be exceeded. In the case of administration of relatively large amounts, it may be advisable to divide these into several individual doses over the course of the day.
inorganic pigments, for example iron oxides) and flavour and/or odour correctants.
In general, it has been found to be advantageous in the case of parenteral administration to administer amounts of about 0.001 to 1 mg/kg, preferably about 0.01 to 0.5 mg/kg, of body weight to achieve effective results. In the case of oral administration, the dosage is about 0.01 to 100 mg/kg, preferably about 0.01 to 20 mg/kg and most preferably 0.1 to 10 mg/kg of body weight.
For Finerenone administration in the pediatric population a dose of 5 to 40 mg, preferably 10 to 20 mg once daily for children with body weights in the adult range (approximatel 70 to 80kg) is the preferred dosage range.
For children with lower body weights (below 70 to 80 kg) a dose range will be calculated to achieve a similar exposure as observed in adults treated with doses of 5 to 40 mg respectively 10 to 20 mg once daily.
(Edginton AN, Schmitt W, Willmann S. Clin Pharmacokinet. 2006;45(10) :1013 -34).
It may nevertheless be necessary where appropriate to deviate from the stated amounts, specifically as a function of the body weight, route of administration, individual response to the active compound, nature of the preparation and time or interval over which administration takes place.
For instance, in some cases, less than the aforementioned minimum amount may be sufficient, while in other cases the upper limit mentioned must be exceeded. In the case of administration of relatively large amounts, it may be advisable to divide these into several individual doses over the course of the day.
-27-Experimental Part Abbreviations:
Ecc Eccentric contraction het. heterozygous Hz Hertz ms milliseconds n number (of experimental units) ND not determined PN Pressure/Volume RT/PCR Reverse transcription polymerase chain reaction SEM Standard Error of the Mean
Ecc Eccentric contraction het. heterozygous Hz Hertz ms milliseconds n number (of experimental units) ND not determined PN Pressure/Volume RT/PCR Reverse transcription polymerase chain reaction SEM Standard Error of the Mean
-28-Investigation of therapeutic efficacy:
For investigations of the effects of non-steroidal MRAs as monotherapy treatment or in combination with sGC stimulators and/or sGC activators, a broad spectrum of in vitro, ex vivo and in vivo tests were used.
Preferentially mice were used, especially transgenic mice (B6.Cg-Terctm 1Rdp Dmdmdx-4Cv /BlauJ; Jackson Laboratories, strain Nr.: 023535; Dystrophin-deficient, utrophin haplo-insufficient (utrn +/¨ ; mdx)). These so called MDX mice carry a mutation in the dystrophin gene which reflects the phenotype and clinical situation of patients with muscular dystrophies (Sacco et al.; Cell. 2010 Dec 23;143(7):1059-71, Mourkioti et al. Nat Cell Biol. 2013 Aug;15(8):895-904).
As read-outs were preferentially used:
= In vitro, hydroxyproline measurement to assess fibrotic tissue. To analyze the collagen content in tissue samples, hydroxyproline assays were performed. After digestion of the tissue (e.g. heart and muscle) in 6M HC1 for three hours at 120 C, chloramine T (0.06 M) was added and samples were mixed and incubated for 20 min at room temperature. 3.15 M perchloric acid and 20 % p-dimethylaminobenzaldehyde were added and samples were incubated for additional 20 min at 60 C. The absorbance was determined at 557 nm.
= In vitro, semiquantitative RT/PCR (TaqMan PCR) was used to assess gene expression. Mice were euthanized and hearts and muscles (e.g. EDL = extensor digitorum longus muscle, diaphragm) were collected. Total RNA was isolated and gene expression was semiquantified after reverse transcription (RT) reaction via TaqMan polymerase chain reaction (PCR).
= In vitro, histopathology to assess heart and muscle damage. Mice were euthanized and hearts and muscles (e.g. EDL, diaphragm) were collected. Cryosections were prepared and stained with Hematoxylin and Eosin (H&E) to assess overall histopathology.
= Ex vivo, contractility measurements of muscle contraction in isolated muscles (e.g. EDL, diaphragm) to assess muscle function and contractility. Isolated muscles were stretched to optimal length using twitch contractions (evoked by a single 4 ms pulse). After 10 minutes, a tetanus contraction was performed (150 Hz for 250 ms). After another 5 min rest period, 6 eccentric contractions (150 Hz for 450 ms, subjected to a 3% stretch for the final 200 ms of contraction) were done with two minutes of rest between the first 5 stimulations and 15 minutes of rest between the fifth and sixth stimulation.
= In vivo, non-invasive echocardiography and computer tomography to assess heart and cardiovascular function. Mice were anaesthetized and heart structure and function was assessed non-invasively by using the echocardiograph type Vevo2100. In addition, cardiac function was
For investigations of the effects of non-steroidal MRAs as monotherapy treatment or in combination with sGC stimulators and/or sGC activators, a broad spectrum of in vitro, ex vivo and in vivo tests were used.
Preferentially mice were used, especially transgenic mice (B6.Cg-Terctm 1Rdp Dmdmdx-4Cv /BlauJ; Jackson Laboratories, strain Nr.: 023535; Dystrophin-deficient, utrophin haplo-insufficient (utrn +/¨ ; mdx)). These so called MDX mice carry a mutation in the dystrophin gene which reflects the phenotype and clinical situation of patients with muscular dystrophies (Sacco et al.; Cell. 2010 Dec 23;143(7):1059-71, Mourkioti et al. Nat Cell Biol. 2013 Aug;15(8):895-904).
As read-outs were preferentially used:
= In vitro, hydroxyproline measurement to assess fibrotic tissue. To analyze the collagen content in tissue samples, hydroxyproline assays were performed. After digestion of the tissue (e.g. heart and muscle) in 6M HC1 for three hours at 120 C, chloramine T (0.06 M) was added and samples were mixed and incubated for 20 min at room temperature. 3.15 M perchloric acid and 20 % p-dimethylaminobenzaldehyde were added and samples were incubated for additional 20 min at 60 C. The absorbance was determined at 557 nm.
= In vitro, semiquantitative RT/PCR (TaqMan PCR) was used to assess gene expression. Mice were euthanized and hearts and muscles (e.g. EDL = extensor digitorum longus muscle, diaphragm) were collected. Total RNA was isolated and gene expression was semiquantified after reverse transcription (RT) reaction via TaqMan polymerase chain reaction (PCR).
= In vitro, histopathology to assess heart and muscle damage. Mice were euthanized and hearts and muscles (e.g. EDL, diaphragm) were collected. Cryosections were prepared and stained with Hematoxylin and Eosin (H&E) to assess overall histopathology.
= Ex vivo, contractility measurements of muscle contraction in isolated muscles (e.g. EDL, diaphragm) to assess muscle function and contractility. Isolated muscles were stretched to optimal length using twitch contractions (evoked by a single 4 ms pulse). After 10 minutes, a tetanus contraction was performed (150 Hz for 250 ms). After another 5 min rest period, 6 eccentric contractions (150 Hz for 450 ms, subjected to a 3% stretch for the final 200 ms of contraction) were done with two minutes of rest between the first 5 stimulations and 15 minutes of rest between the fifth and sixth stimulation.
= In vivo, non-invasive echocardiography and computer tomography to assess heart and cardiovascular function. Mice were anaesthetized and heart structure and function was assessed non-invasively by using the echocardiograph type Vevo2100. In addition, cardiac function was
-29-investigated in anesthetized mice by using magnetic resonance imaging (MRI) technique on a 9.4 or 11.7 Tesla 30mm bore system (Bruker Biospin) together with standard electrocardiographic (ECG).
Myocardial strain and strain rate were assessed using vector-based tracking software (Vector Velocity Imaging, Siemens).
= In vivo, invasive left-ventricular function and pressure-volume relationship to assess heart and cardiovascular function. Invasive left-ventricular hemodynamics were performed in anaesthetized mice using a pressure catheter and a P/V loop catheter.
= In vivo assessment of muscle force (Hanging wire test, four limb hanging test, grip strength test) to asses muscle function. For the hanging wire and four limb hanging test, conscious mice are freely hanging on a grid and hanging time is recorded and corrected for body weight of the mice. The grip strength (GS) measurements to investigate front-leg muscle strength were performed in conscious mice by using a grip strength meter (Columbus Instruments). Mice were trained to hold on with their front paws on a wire mesh grid and carefully pulled backwards. This procedure was repeated up to 5 times with one minute breaks between measurements and the maximal power in Newton (N) was registered. The highest grid strength value (GS) in Newton was reported and related to body weight (BW) in mg. All grip strength measurements for each study were conducted by the same investigator to avoid examiner-specific variability and displayed as GS/BW in [N/mg] (Table 1).
= In vivo assessment of physical capacity was assessed. Mice were kept in single mouse cages, equipped with running wheels (treadmills) to assess maximal running velocity and running distance.
Myocardial strain and strain rate were assessed using vector-based tracking software (Vector Velocity Imaging, Siemens).
= In vivo, invasive left-ventricular function and pressure-volume relationship to assess heart and cardiovascular function. Invasive left-ventricular hemodynamics were performed in anaesthetized mice using a pressure catheter and a P/V loop catheter.
= In vivo assessment of muscle force (Hanging wire test, four limb hanging test, grip strength test) to asses muscle function. For the hanging wire and four limb hanging test, conscious mice are freely hanging on a grid and hanging time is recorded and corrected for body weight of the mice. The grip strength (GS) measurements to investigate front-leg muscle strength were performed in conscious mice by using a grip strength meter (Columbus Instruments). Mice were trained to hold on with their front paws on a wire mesh grid and carefully pulled backwards. This procedure was repeated up to 5 times with one minute breaks between measurements and the maximal power in Newton (N) was registered. The highest grid strength value (GS) in Newton was reported and related to body weight (BW) in mg. All grip strength measurements for each study were conducted by the same investigator to avoid examiner-specific variability and displayed as GS/BW in [N/mg] (Table 1).
= In vivo assessment of physical capacity was assessed. Mice were kept in single mouse cages, equipped with running wheels (treadmills) to assess maximal running velocity and running distance.
-30-Examples:
Table 1 Groups/Treatment Control Untreated BAY 41-2272 Finerenone Mean SEM Mean SEM Mean SEM Mean SEM (n) (n) (n) (n) Grip Strength trial 1 (N) 1.5 0.05 1.0 0.05 (15) 1.0 0.04 (17) 1.1 0.04 (16) (15) GS/BW trial 1 (N/mg) 58.2 1.5 35.2 1.5 (15) 38.3 1.1 (17) 40.3 1.0 (16) (15) Grip Strength trial 5 (N) 1.5 0.05 0.8 0.04 (15) 0.9 0.04 (17) 1.1 0.04 (16) (15) GS/BW trial 5 (N/mg) 56.5 1.7 29.7 1.1 (15) 33.9 0.9 (17) 37.5 1.1 (16) (15) Base_PeakSysSR_Mean ND 0.31 0.03 0.36 0.02 0.35 0.03 (11) (endocardial (12) (12) circumferential S-1) Base_PeakSysSR_Septum ND 0.33 0.03 0.39 0.03 0.34 0.04 (11) (endocardial (12) (12) circumferential S-1) Base_PeakSysSR_Lat ND 0.28 0.03 0.37 0.02 0.39 0.04 (11) (endocardial (12) (12) circumferential S-1) Ecc2 (% Eccl) 98 1 (17) 82 2 (18) 86 2 (17) 94 5 (18) Ecc5 (% Eccl) 86 2(17) 51 4(18) 60 5 (17) 71 7 (18) Post-rest Ecc6 (% Eccl) 90 2(17) Si 4 (18) 60 5 (17) 72 6 (18) These results show surprisingly that treatment with Finerenone monotherapy is superior to the treatment to a combination of steroidal MR-antagonists with an ACE-Inhibitor (the latter is part of the standard-of-care treatment in DMD) (Lowe et al., J Neuromuscul Dis. 2016; 3(3): 395-404, Lowe et al. J Neuromuscul Dis.
2018;5(3):295-306.).
Table 1 Groups/Treatment Control Untreated BAY 41-2272 Finerenone Mean SEM Mean SEM Mean SEM Mean SEM (n) (n) (n) (n) Grip Strength trial 1 (N) 1.5 0.05 1.0 0.05 (15) 1.0 0.04 (17) 1.1 0.04 (16) (15) GS/BW trial 1 (N/mg) 58.2 1.5 35.2 1.5 (15) 38.3 1.1 (17) 40.3 1.0 (16) (15) Grip Strength trial 5 (N) 1.5 0.05 0.8 0.04 (15) 0.9 0.04 (17) 1.1 0.04 (16) (15) GS/BW trial 5 (N/mg) 56.5 1.7 29.7 1.1 (15) 33.9 0.9 (17) 37.5 1.1 (16) (15) Base_PeakSysSR_Mean ND 0.31 0.03 0.36 0.02 0.35 0.03 (11) (endocardial (12) (12) circumferential S-1) Base_PeakSysSR_Septum ND 0.33 0.03 0.39 0.03 0.34 0.04 (11) (endocardial (12) (12) circumferential S-1) Base_PeakSysSR_Lat ND 0.28 0.03 0.37 0.02 0.39 0.04 (11) (endocardial (12) (12) circumferential S-1) Ecc2 (% Eccl) 98 1 (17) 82 2 (18) 86 2 (17) 94 5 (18) Ecc5 (% Eccl) 86 2(17) 51 4(18) 60 5 (17) 71 7 (18) Post-rest Ecc6 (% Eccl) 90 2(17) Si 4 (18) 60 5 (17) 72 6 (18) These results show surprisingly that treatment with Finerenone monotherapy is superior to the treatment to a combination of steroidal MR-antagonists with an ACE-Inhibitor (the latter is part of the standard-of-care treatment in DMD) (Lowe et al., J Neuromuscul Dis. 2016; 3(3): 395-404, Lowe et al. J Neuromuscul Dis.
2018;5(3):295-306.).
-31-Investigation of therapeutic efficacy:
For investigations of the effects of non-steroidal MRAs as monotherapy treatment or in combination with sGC stimulators and/or sGC activators, a broad spectrum of in vitro, ex vivo and in vivo tests were used.
Preferentially mice were used, especially transgenic mice (B6.Cg-Terctm1Rdp Dmdmdx-4Cv/BlauJ;
Jackson Laboratories, strain Nr.: 023535). These so called MDX mice carry a mutation in the dystrophin gene which reflects the phenotype and clinical situation of patients with muscular dystrophies. (Sacco et al.;
Cell. 2010 Dec 23;143(7):1059-71, Mourkioti et al. Nat Cell Biol. 2013 Aug;15(8):895-904).
Grip Strength (GS)/ Body Weight (BW) ratio in [N/mg] in WT mice and MDX-mice treated for 16 weeks with either placebo chow, or chow supplemented with 150 ppm sGC stimulator BAY
41-2272, or chow supplemented with 100 ppm non-steroidal MR Antagonist Finerenone. Grip strength determination: Five series of five pulls each with a pause of 1 minute in between the series were performed. The highest value in the first trial was taken as the highest force produced from rested mice and the highest value in the fifth trial was taken as the highest force produced in fatigued mice. These data indicate an improvement of muscle strength after treatment with sGC stimulator BAY 41-2272 alone as well as non-steroidal MR Antagonist Finerenone alone.
The mean of the endocardial circumferential peak of the systolic strain rate determined from the base of the heart (Base_PeakSysSR_Mean (endocardial circumferential S-1)), in WT mice and MDX-mice treated for 16 weeks with either placebo chow, or chow supplemented with 150 ppm sGC
stimulator BAY 41-2272, or chow supplemented with 100 ppm non-steroidal MR Antagonist Finerenone were measured. In Duchenne muscular dystrophy, strain rate reduction indicates myocardial damage. These data indicate an attenuation of heart function decline after treatment with sGC stimulator and non-steroidal MR Antagonist.
EDL eccentric contractions (Ecc) in WT mice and MDX-mice treated for 16 weeks with either placebo chow, or chow supplemented with 150 ppm sGC stimulator BAY 41-2272, or chow supplemented with 100 ppm non-steroidal MR Antagonist Finerenone were measured. This protocol assesses reduced force due to damage and reduced force due to fatigue by comparing excentric-contractions coupling 5 and 6. Reduced force due to the membrane damage seen in dystrophy starts to happen after the first or 2nd eccentric contraction. These data indicate improvement of muscle strength after treatment with sGC stimulator and non-steroidal MR Antagonist.
For investigations of the effects of non-steroidal MRAs as monotherapy treatment or in combination with sGC stimulators and/or sGC activators, a broad spectrum of in vitro, ex vivo and in vivo tests were used.
Preferentially mice were used, especially transgenic mice (B6.Cg-Terctm1Rdp Dmdmdx-4Cv/BlauJ;
Jackson Laboratories, strain Nr.: 023535). These so called MDX mice carry a mutation in the dystrophin gene which reflects the phenotype and clinical situation of patients with muscular dystrophies. (Sacco et al.;
Cell. 2010 Dec 23;143(7):1059-71, Mourkioti et al. Nat Cell Biol. 2013 Aug;15(8):895-904).
Grip Strength (GS)/ Body Weight (BW) ratio in [N/mg] in WT mice and MDX-mice treated for 16 weeks with either placebo chow, or chow supplemented with 150 ppm sGC stimulator BAY
41-2272, or chow supplemented with 100 ppm non-steroidal MR Antagonist Finerenone. Grip strength determination: Five series of five pulls each with a pause of 1 minute in between the series were performed. The highest value in the first trial was taken as the highest force produced from rested mice and the highest value in the fifth trial was taken as the highest force produced in fatigued mice. These data indicate an improvement of muscle strength after treatment with sGC stimulator BAY 41-2272 alone as well as non-steroidal MR Antagonist Finerenone alone.
The mean of the endocardial circumferential peak of the systolic strain rate determined from the base of the heart (Base_PeakSysSR_Mean (endocardial circumferential S-1)), in WT mice and MDX-mice treated for 16 weeks with either placebo chow, or chow supplemented with 150 ppm sGC
stimulator BAY 41-2272, or chow supplemented with 100 ppm non-steroidal MR Antagonist Finerenone were measured. In Duchenne muscular dystrophy, strain rate reduction indicates myocardial damage. These data indicate an attenuation of heart function decline after treatment with sGC stimulator and non-steroidal MR Antagonist.
EDL eccentric contractions (Ecc) in WT mice and MDX-mice treated for 16 weeks with either placebo chow, or chow supplemented with 150 ppm sGC stimulator BAY 41-2272, or chow supplemented with 100 ppm non-steroidal MR Antagonist Finerenone were measured. This protocol assesses reduced force due to damage and reduced force due to fatigue by comparing excentric-contractions coupling 5 and 6. Reduced force due to the membrane damage seen in dystrophy starts to happen after the first or 2nd eccentric contraction. These data indicate improvement of muscle strength after treatment with sGC stimulator and non-steroidal MR Antagonist.
Claims (12)
1. A non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof for use in the treatment and/or prevention of a muscular or neuromuscular disease.
2. The non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof for use according to claim 1, wherein the muscular or neuromuscular disease is a muscular dystrophy.
3. The non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof for use according to any one of claims 1 or 2, wherein the disease is Duchenne muscular dystrophy (DMD).
4. The non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof for use according to any one of claims 1 to 3, wherein the non-steroidal MR Antagonist is Finerenone (S)-4-(4-Cyano-2-methoxypheny1)-5-ethoxy-2,8-dimethy1-1,4-dihydro-1,6-naphthyridin- 3-carboxamid) according to formula (I) N
OMe Et H
(I) or a pharmaceutically acceptable salt thereof.
OMe Et H
(I) or a pharmaceutically acceptable salt thereof.
5. A pharmaceutical composition comprising a non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof, and at least one more additional therapeutic agent, for use in the treatment of a muscular or neuromuscular disease.
6. Pharmaceutical composition according to claim 5, whereas the at least one more additional therapeutic agent is a sGC Stimulator.
7. Pharmaceutical composition according to any of claims 5 or 6, whereas the sGC Stimulator is selected from the group consisting of = methyl 4,6-diamino-2- [1 -(2- fluorobenzyl)-1H-pyrazolo [3,4-b] pyridin-3 -yl] -5 -pyrimidinyl(methyl)carbamate (Riociguat), = methyl {4,6-diamino-2- [5 -fluoro-1 -(2 -fluorobenzyl)-1H-pyrazolo [3 ,4-b] pyridine-3 -yl] pyrimidin-5 -y1 } carbamate (Vericiguat), = 3 -(4-amino-5-cyclopropylpyrimidin-2 -y1)-1 -(2 -fluorobenzyl)-1H-pyrazolo [3 ,4-b] pyridine (BAY 41-2272) and = 1 ,1,1,3 ,3 ,3 -Hexafluoro-2- [( {5 -fluoro-2- [142 -fluorobenzyl)-5 -(1,2- oxazol-3 -y1)-1 H-pyrazol-3 -yl] -4-pyrimidinyll amino)methyl] -2-propanol (Praliciguat) or a pharmaceutically acceptable salt thereof.
8. Pharmaceutical composition according to any of claims 5 to 7, whereas the sGC Stimulator is 3-(4-amino-5 -cyclopropylpyrimidin-2-y1)-1 -(2- fluorobenzyl)-1H-pyrazolo [3,4 -b ]pyridine (BAY 41 -2272) or a pharmaceutically acceptable salt thereof.
9. Medicament, comprising a non-steroidal MR Antagonist or a pharmaceutically acceptable salt thereof for use according to any one of claims 1 to 4 in combination with one or more inert non-toxic pharmaceutically suitable auxiliaries.
10. Medicament, comprising a pharmaceutical composition for use according to any one of claims 5 to 8 in combination with one or more inert non-toxic pharmaceutically suitable auxiliaries.
11. Method for the treatment and/or prevention of a muscular or neuromuscular disease in humans and animals by administration of an effective amount of at least one compound as defined in any of claims 1 to 4 or of a medicament as defined claim 9.
12. Method for the treatment and/or prevention of a muscular or neuromuscular disease in humans and animals by administration of an effective amount of at least one pharmaceutical composition as defined in any of claims 5 to 8 or of a medicament as defined claim 10.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18171857.8A EP3566704A1 (en) | 2018-05-11 | 2018-05-11 | The use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases |
EP18171857.8 | 2018-05-11 | ||
PCT/EP2019/062021 WO2019215317A1 (en) | 2018-05-11 | 2019-05-10 | The use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3099614A1 true CA3099614A1 (en) | 2019-11-14 |
Family
ID=62152463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3099614A Pending CA3099614A1 (en) | 2018-05-11 | 2019-05-10 | The use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases |
Country Status (6)
Country | Link |
---|---|
US (1) | US11439628B2 (en) |
EP (2) | EP3566704A1 (en) |
JP (1) | JP2021523180A (en) |
CN (1) | CN112105358B (en) |
CA (1) | CA3099614A1 (en) |
WO (1) | WO2019215317A1 (en) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102010021637A1 (en) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituted 5-fluoro-1H-pyrazolopyridines and their use |
US9624214B2 (en) | 2012-11-05 | 2017-04-18 | Bayer Pharma Aktiengesellschaft | Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use |
WO2014190250A1 (en) | 2013-05-23 | 2014-11-27 | The Johns Hopkins University | Activators of soluable guanylate cyclase and their use in treatment of duchenne muscular dystrophy and related disease |
EP3094327A1 (en) * | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
WO2017029261A1 (en) * | 2015-08-19 | 2017-02-23 | Bayer Pharma Aktiengesellschaft | Combination drug comprising finerenone and an nep-inhibitor (sacubitril) |
MX367960B (en) | 2015-08-21 | 2019-09-12 | Bayer Pharma AG | Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5- ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient. |
JP7101688B2 (en) * | 2016-10-11 | 2022-07-15 | バイエル・ファルマ・アクティエンゲゼルシャフト | Combinations containing sGC stimulants and mineral corticoid receptor antagonists |
CA3039735A1 (en) * | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Combination containing sgc activators and mineralocorticoid receptor antagonists |
-
2018
- 2018-05-11 EP EP18171857.8A patent/EP3566704A1/en not_active Withdrawn
-
2019
- 2019-05-10 CN CN201980031542.6A patent/CN112105358B/en active Active
- 2019-05-10 JP JP2020563702A patent/JP2021523180A/en active Pending
- 2019-05-10 US US17/051,923 patent/US11439628B2/en active Active
- 2019-05-10 WO PCT/EP2019/062021 patent/WO2019215317A1/en active Application Filing
- 2019-05-10 EP EP19722620.2A patent/EP3790546A1/en active Pending
- 2019-05-10 CA CA3099614A patent/CA3099614A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN112105358A (en) | 2020-12-18 |
US20210121447A1 (en) | 2021-04-29 |
CN112105358B (en) | 2023-10-13 |
US11439628B2 (en) | 2022-09-13 |
EP3566704A1 (en) | 2019-11-13 |
EP3790546A1 (en) | 2021-03-17 |
WO2019215317A1 (en) | 2019-11-14 |
JP2021523180A (en) | 2021-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6508544B2 (en) | Pharmaceutical composition for treating a tumor | |
JP5666910B2 (en) | Kits, compositions, products or medicaments for treating cognitive impairment | |
CA2582436C (en) | Combinations of nicotinic acetylcholine alpha 7 receptor agonists | |
JP2021042248A (en) | Treatment of diastolic cardiac dysfunction with trpv2 receptor agonist | |
TW200524611A (en) | Methods of preventing and reducing the severity of stress-associated conditions | |
AU2023202121A1 (en) | Therapeutic agents for neurodegenerative diseases | |
JP6145778B2 (en) | Preventive or therapeutic agent for idiopathic inflammatory myopathy | |
EP3094327A1 (en) | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | |
US20190192525A1 (en) | Apilimod compositions and methods for using same | |
JP2000505094A (en) | Treatment of upper respiratory allergic response using a combination of histamine receptor antagonists | |
JP2008517974A (en) | Use of dipyridamole for the treatment and prevention of thromboembolic diseases in combination with antithrombotic drugs | |
US20230115611A1 (en) | Treatment of pain and vasoconstriction | |
AU5198301A (en) | The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease | |
WO2004067006A1 (en) | Combination of a pde iv inhibitor and a tnf-alpha antagonist | |
PT2089031E (en) | Reduction of overweight or obesity | |
KR101199730B1 (en) | Use of substituted 1,2,3 indolizine derivatives for treating diseases associated with a pathological choroidal angiogenesis | |
US11439628B2 (en) | Use of non-steroidal mineralocorticoid receptor antagonists alone or in combination for the treatment of muscular or neuromuscular diseases | |
CN114072205A (en) | Method of treating hypertension with TIE-2 activator | |
US20230355618A1 (en) | Raf inhibitor for treating low grade glioma | |
AU2018351709B2 (en) | Therapeutic agents for neurodegenerative diseases | |
JP2009532498A (en) | Combination of organic compounds | |
WO1999055339A1 (en) | Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and renal function | |
NEWCORN et al. | α2-Adrenergic Agonists: Clonidine and Guanfacine | |
ULC | Aldosterone Antagonist | |
De Jager et al. | Sildenafil in the treatment of pulmonary hypertension in the neonate: paediatrics |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20240408 |